RESPONSE ADAPTIVE CLINICAL TRIALS WITH CENSORED LIFETIMES by Xun, Dong
RESPONSE ADAPTIVE CLINICAL TRIALS WITH
CENSORED LIFETIMES
A Thesis Submitted to the
College of Graduate Studies and Research
in Partial Fulfillment of the Requirements
for the degree of Master of Science
in the Department of Mathematics and Statistics
University of Saskatchewan
Saskatoon
By
Xun Dong
c©Xun Dong, October, 2013. All rights reserved.
Permission to Use
In presenting this thesis in partial fulfilment of the requirements for a Postgraduate degree from the
University of Saskatchewan, I agree that the Libraries of this University may make it freely available for
inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for
scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their
absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is
understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not
be allowed without my written permission. It is also understood that due recognition shall be given to me
and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis.
Requests for permission to copy or to make other use of material in this thesis in whole or part should
be addressed to:
Head of the Department of Mathematics and Statistics
Room 142 McLean Hall
106 Wiggins Road
Saskatoon, Saskatchewan
CANADA
S7N 5E6
i
Abstract
We have constructed a response adaptive clinical trial to treat patients sequentially in order to maximize
the total survival time of all patients. Typically the response adaptive design is based on the urn models
or on sequential estimation procedures, but we used a bandit process in this dissertation. The objective of
a bandit process is to optimize a measure of sequential selections from several treatments. Each treatment
consist of a sequence of conditionally independent and identically distributed random variables, and some of
these treatment have unknown distribution functions. For the purpose of this clinical trial, we are focusing on
the bandit process with delayed response. These responses are lifetime variables which may be censored upon
their observations. Following the Bayesian approach and dynamic programming technique, we formulated a
controlled stochastic dynamic model. In addition, we used an example to illustrate the possible application
of the main results as well as R to implement a model simulation.
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Chapter 1
Introduction
1.1 Background
It is widely accepted by the scientific community that a clinical trial is the most reliable and efficient way to
evaluate the efficacy of new medical interventions, therapeutic or prophylactic. Randomization has always
been an essential feature for designing such clinical trials. It prevents selection bias and insures against
accidental bias. The traditional randomization has been regarded as the gold standard for clinical trials.
In particular, the permuted block design is the most popular randomization procedure applied in practice.
However, as an experiment on human subjects, maintaining the balance between collective ethics and in-
dividual ethics is difficult in clinical trials. In some desperate clinical trials, such as cancer, the patient is
suffering from a serious, acute, and potentially debilitating or terminal illness. The collective ethics fall into
a disadvantaged position, and the traditional balanced randomization becomes unavailable because of the
unjustifiable sacrifice of individual ethics. Instead, response adaptive randomization is ethically justified and
morally required[23].
An important class of clinical trial designs is adaptive randomization, which has been a fruitful area of
research. Adaptive randomization refers to any scheme in which the allocation probability changes according
to response of treatment in the trial. In the past decade many books and top statistical journals have studied
this subject. Two recent book chapters detail the modern statistical theory and practice of adaptive ran-
domization: Pong and Chow[26] and Hinkelmann[18]. Many recent developments also focused on providing a
template for the selection of appropriate procedures and guidance for their use in practice. For example, the
U.S. Food and Drug Administration (FDA, 2010) drafted a guide to regulatory aspects of adaptive random-
ization designs. A response adaptive randomization can be considered as a data dependent design of clinical
trials. The goal is to improve the clinical trials’ efficiency and ethics without undermining the validity and
integrity of the clinical research[43]. Typically the response adaptive design is based on urn models or on
sequential estimation procedures[15], but a more promising approach is to use the decision theoretic model
of bandit process[4]. The advantage of the bandit model is that it is deterministic and achieves an optimal
solution[7]. For more details on adaptive designs applied in clinical trials, Yi and Wang[45] did a general
review of methods, issues and inference procedures of response. In addition, a prototypical example will be
discussed later.
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While response adaptive randomization procedures are not appropriate in clinical trials with a limited
recruitment period and outcomes that occur after all patients have been randomized, there is no reason why
response adaptive randomization cannot be used in clinical trials with moderate delayed responses[32]. The
delayed response just represents the delayed times for the responses of the treatments in clinical trial. In
addition, there is much literature showing that, under widely applicable conditions, large sample are unaf-
fected by delayed responses for the: doubly-adaptive biased coin design[17], urn models[5, 14, 48], and bandit
model[40]. From a practical perspective, there is no difficulty in applying delayed responses to the response
adaptive randomization procedure provided that responses become available during the recruitment and ran-
domization period. The information update can also be made after groups of patients or individual patients
have responded. In this dissertation, we will construct a controlled stochastic dynamic model to discover some
properties of the optimal deterministic strategy for the bandit process. Our model comes from Wang’s[40]
bandit model modified. After deriving our main results, we will also highlight a possible application for
designing response adaptive clinical trials. Based on this application, we redid Wang’s simulations and found
there are some initialization problems in his program. In Wang’s PhD thesis[40], he simulated two patients
case, three patients case, and fourteen patients case, all these simulations were programmed in Fortran[12].
In my simulation, I redesigned the program by R[33] and included many more different situations, such as
different expect arrival time and different known expect survival time. More details are fully investigated in
our follow up research.
1.2 Prototypical example
Consider a clinical trial in which two different treatments A and B are available for a disease (such as can-
cer, for example). Patients with this disease are recruited to participate in the trial. The patients’ actual
lifetimes after treatment is our primary concern, and our objective is to maximize the measure of the total
of the patients’ expected lifetimes after treatment. The assumption is that each patient is treated only with
one treatment. If supposedly treatment A is a new medical intervention, then its effectiveness is unknown.
After treatment A, all patients’ lifetimes will follow the same lifetime distribution, which is unknown and is
to be estimated. On the other hand, treatment B is standard. That is to say, it has been investigated before
and has well known effectiveness. The patients’ expected lifetime is known after treatment B. After the
treatment, the patients are closely followed by the investigator, and their responses are available at any time.
That is to say, the patients’ actual lifetimes after treatment have become the focal point. After observing
the condition of the patients, the efficacy of the treatment can be inferred.
Assume that there are two independent treatments A and B. Since they are independent, the observa-
tions made during one treatment will not provide any information on the other. The patients are treated
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sequentially one by one, and the time frame between patients is random. We can assume that the time frame
between the treatments of two consecutive patients follow the same arrival distribution and are indepen-
dent of each other. The effectiveness of treatment A is unknown, but we assume that prior information on
treatment A is available. A clinical trial is a responsible and ethical experiment on a human being, so the
patients’ interests are more important than the doctors’. Hence we should always analyze the observations
from previously treated patients on treatment A before a new patient will be treated.
Suppose that at the time a patient is to be treated, the expected lifetime is E(X | A) with treatment
A, and E(X | B) with treatment B, where X is the residual survival time. If treatment A appears to be
no worse than treatment B in terms of expected lifetime of the patients (i.e.E(X | A) ≥ E(X | B)), then
we shall treat this patient with treatment A. On the other hand, if treatment B appears to be better than
treatment A in terms of expected lifetime (i.e.E(X | A) ≤ E(X | B)), then we shall allocate treatment B. In
order to receive a higher expected lifetime for the present patient, we should allocate treatment B. However,
the expectation may change as information is updated. If we would allocate treatment A to the patient,
although we receive a shorter expected lifetime for the present patient, the observation from this patient will
provide information on the efficacy of treatment A in the future. This will improve our understanding of
treatment A, and may lead to higher expected lifetimes for future patients.
The best allocation of treatment to a patient is the biggest problem we encountered in this investigation.
The allocation depends on the nature and amount of information available, the number of patients to be
treated in the future, and the objectives of the trial. The attitude of what constitutes relevant information,
the approach of utilizing the information, and the type of design we choose will also influence our allocation
of the treatment. Since the patient’s lifetime is our primary concern, another difficulty comes from the nature
of the available information. In clinical trials, the term censoring is used to refer to mathematically removing
a patient from the survival curve at the end of their follow-up time due to incomplete information because
we do not know the actual lifetime but only a lower bound[25]. After the treatment, a patient’s lifetime is
continuous, and its observation may be censored at any time. If at a particular time, all patients previously
treated with treatment A are dead, then complete information is available about the effectiveness of treatment
A. Otherwise, only censored observations of some of these patients’ lifetimes are available. Then we would be
facing the problem of missing information about the effectiveness of treatment A. In this case, allocation of
treatment is a difficult decision. It is practically impossible to wait for complete observations of all previously
treated patients’ lifetimes before treating the next patient. The doctors cannot wait, neither can the patients,
because delayed treatment could cause death, or worsen the sickness. Therefore, the allocation has to be
done before complete information is available, and this involves the statistical analysis of censored lifetimes.
The goal of this dissertation is to formulate and analyze sequential treatments with censored lifetimes. We
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will review relevant concepts and issues in the subjects of clinical trials, sequential selections of treatments
and statistical analysis of lifetimes.
1.3 Clinical trials
According to Lee[21], Clinical trials are prospective studies that, under some pre-specified conditions, eval-
uate the effect of medical interventions in humans. Since the 19th century, clinical trials have become a
standard and an integral part of modern medicine. Clinical trials can be used as a tool to better understand
human disease. A properly planned and executed clinical trial is the most definitive tool for evaluating the
effect and applicability of new treatment modalities. Clinical trials have been studied extensively in the
statistical literature; see Piantadosi[24] for methodological perspectives of clinical trials; see DeMets[9] for
current developments in clinical trials; and further investigated in D’Agostino[10], a panel discussion on the
future of clinical trials. In order to better understand clinical trials, we will introduce basic concepts below.
The patient denotes an individual enrolled in clinical trials. Patients usually are divided into separate
groups to receive different treatments. Some will be allocated to the treatment group, while others will be
allocated to a comparison group.
The treatment in a clinical trial can be considered as any medical experiment on the patient. The exper-
iment may be administering a drug, performing an operation, or simply giving the patients a placebo. The
test treatment is a medical intervention to be evaluated in the trial for its efficacy. A clinical trial may involve
one or more test treatments. The control treatment is a standard treatment used for comparison with the
test treatments.
The basic goal of a clinical trial is to estimate the efficacy of treatment and to treat the patient as effec-
tively as possible. In order to assess the efficacy from different treatments, the designer normally allocates
the matched stratified design to all groups.
A clinical trial normally involves four phases: design, execution, analysis, and reporting. Our research
concentrated on phase one, which are designed to establish the basic safety and efficacy of a test treatment.
A successful clinical trial needs to meet basic prerequisites, and the objectives must be precise and clear. If
a design has several purposes, the most important one should be explicitly defined.
Since the patients’ responses are biological, they will inevitably vary if the same treatment is applied to
the different patients with the same disease, or to the same patient repeatedly. Therefore, the variation in
responses are due to the treatments and individual uncertainties. In order to avoid this as much as possible,
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the criteria for recruiting patients into clinical trials should also be well defined.
1.4 Adaptive randomization
Randomization is a fundamental component of a well conducted clinical trial. Randomization ensures the
comparability of treatment groups and mitigates the selection bias in the design. It plays a critical role among
advances in the history of medical research. The traditional randomization has been regarded as the gold
standard for clinical trials, such as permuted block randomization in which the number of subjects in each
block are specified, and subjects are allocated randomly within each block. It is the most popular random-
ization procedure applied in practice. However, it may not be optimal in many clinical trials where multiple
experimental objectives are pursued. Another important class of randomization applied in clinical trials is
adaptive randomization. It is a change in allocation probabilities during the course of the trial to promote
multiple experimental objectives, while protecting the study from bias and preserving inferential validity of
the results[32]. Most clinical trials are multi-objective, and it is hard to find a single design criterion that
describes all objectives. However, adaptive randomization can be considered as a solution to an optimization
problem which accommodates several selected design criterion. In the design phase, some of the objectives
will depend on model parameters which are unknown. During the course of the trial, adaptive randomization
is useful and sometimes imperative to redesign the trial to achieve these objectives. In addition, the tradi-
tional randomization is not applicable in some desperate clinical trials since there is an unjustifiable sacrifice
of individual ethics. Therefore, adaptive randomization has an inherent advantage and our model based on
the response-adaptive randomization. It is a randomization procedure that uses past treatment assignments
and patient responses to select the future treatment assignments, with the objective to maximize power and
minimize the probability of treatment failures.
Response-adaptive randomization has been studied extensively in statistical literature. Pioneering works
can be traced to Thompson[38] and Robbins[28]. Extensive research has been done by Anscombe[1] and
Colton[6], with more recent developments in this area by Rosenberger and Lachin[30]. A more detailed
history of the subject is discussed in Rosenberger, Sverdlov and Hu[32]. The most famous nonrandomized
response-adaptive methodology is play-the-winner rule[46], in which a success with a treatment leads to
the assignment of the next patient to the same treatment, and failure would assign the next patient to the
opposite treatment. The first randomized response-adaptive methodology was designed by incorporating
randomization into the play-the-winner rule, and was named the randomized play-the-winner rule[39]. With
this approach, the patient’s treatment assignment keeps the spirit of the play-the-winner rule, but the patient
can be modelled by drawing a ball from an urn, and the urn composition is updated based on the previous
responses so that there are more balls corresponding to the better treatment. Based on the randomized
play-the-winner rule, most research on response-adaptive randomization is based on the stochastic processes
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such as urn models[2] and bandit processes[3]. Modern research on response-adaptive randomization has fo-
cused on the development of optimal response-adaptive randomization procedures that maintain or increase
power over traditional balanced randomization designs, and minimize expected treatment failures for clini-
cal trials with two or more treatment groups[32]. In the past decade, the most representative advance on
response-adaptive randomization is drop-the-loser rule[19] which is a fully randomized procedure based on
the urn model with minimal variability. Generalizations of the drop-the-loser rule can be found in Sun et
al.[35] and Zhang et al.[48]. Although the urn model received the most attention in the latter part of the
20th century[31], we will focus on the bandit model in this dissertation, and will discuss this in more detail
in the next section.
1.5 Bandit processes
In clinical trials, a sequential design is a method for minimizing the number of patients on the inferior treat-
ment, and analyzing and monitoring data continually as it becomes available[26]. The sequential design
normally takes advantage of accruing information to optimize experimental objectives, and assumes that the
only decision to be made is whether the trial should continue or be terminated depending on the effect.
Bandit processes are sequential decision problems with successive selections from different arms, which rep-
resent treatments in clinical trials. Each arm of the bandit process represents a treatment which consists of
a sequence of random responses given by a conditionally independent and identical distribution with known
or unknown parameters. At each stage, the designer must decide which arm to apply next. Selecting an arm
means choosing a treatment for observation. This means assigning a treatment to the next patient in the
clinical trial. The choice normally depends on a trade-off between exploiting arms with utility that appear
to be doing well, and exploring arms that might potentially be optimal in the future, but appear to be weak
at present. The goal of the bandit process is to maximize the objective function of responses from all selec-
tions. The bandit process was first posed by Thompson[38] but received no attention until it was studied by
Robbins[28]. Following the research of Berry and Fristedt[3] and Gittins[13], the bandit process has had an
extensive development. Gittins went on to redefine the bandit process as the semi-Markov decision process.
Typically, the bandit problem is applied in a multi-armed bandit process, which is a sequential experiment
with the goal of achieving the largest possible expect value from a distribution with unknown parameters[36].
The multi-armed bandit process has at least two arms. For example, a simple case of a one-armed bandit
process can be a sequential experiment with two arms, one with a known distribution and the other with an
unknown distribution. According to our prototypical example, the one-armed bandit process is very suitable
for our design ideas. We will do a detailed discussion of its model, states and strategies in Chapter 3.
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1.6 Statistical analysis of lifetimes
Mathematically, a lifetime is a non-negative real-valued random variable in a probability space. The statisti-
cal analysis of lifetimes is called survival analysis, which is defined broadly as the time to the occurrence of a
given event. This event can be the development of a disease, response to a treatment, relapse, or death[20].
In clinical trials, we normally want to compare the lifetimes in two groups to see whether the lifetimes of
individuals in one group are systematically longer than those in the other. However, lifetimes of individuals
in a single group can also be examined to discover other influences. There are many methodologies that
analyze lifetime data, such as various parametric models, nonparametric models, associated distribution-free
methods, graphic procedures, and life tables. The basic design idea is how to specify models in different cir-
cumstances to represent lifetime distributions and to make statistical inference on the basis of these models.
The lifetime distribution may be described in various ways, such as the distribution function, the survival
function, the hazard function, or the mean residual lifetime function. In this dissertation, we mainly focus
on the survival lifetime function.
For a random lifetime variable T , the distribution function is
F (t) = P (T ≤ t),
the survival function is
S(t) = P (T > t) = 1− F (t),
and the mean residual lifetime function is
M(t) = E(T − t|T ≥ t).
If the distribution is absolutely continuous with density function f(t) = F ′(t), the hazard function h(t) is
defined as the instantaneous rate of death at time t, given that T ≥ t, that is
h(t) = lim
∆t→0
P (t ≤ T < t+ ∆t|T ≥ t)
∆t
=
f(t)
S(t)
.
For a discrete random lifetime variable T , which takes on values 0 ≤ t1 < t2 < ..., let the probability mass
function P(t) be given by
P (tj) = P (T = tj), j = 1, 2, ...
In this case the hazard function h(t) is defined by
h(tj) = P (T = tj |T ≥ tj) = P (tj)
S(tj)
, j = 1, 2, ...
These functions all give mathematically equivalent specifications of the distribution of the lifetime variable
T . The hazard function is often the most useful representation because it describes how the instantaneous
probability of death for an individual changes with time. Especially the case when there are special reasons
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to restrict consideration to models with non-increasing hazard functions, or with hazard functions having
some specific characteristics. Qualitatively, hazard functions are sometimes classified as monotone increasing
functions, monotone decreasing functions, bathtub-shaped, or other shaped. There are other distributions
that occupy a central role in the parametric models used to analyze lifetime data, such as exponential dis-
tributions, Weibull distributions, gamma distributions, and log-normal distributions. For more details see
Pappas, Adamidis and Loukas[27].
In the real analysis of lifetime data it is hard to observe the full lengths of the individuals’ lifetimes. In
most clinical trials, not all patients are dead before the end of the trial. If we can only get partial information
on the lifetimes of some individuals, then such datas are censored. The main problem in censored lifetimes
is to determine the sampling distribution and corresponding likelihood function for the process, and to de-
termine the properties of statistical methods derived from this.
Censoring can be classified in several ways[40]. An observation of the lifetime is said to be right censored
at time O if the exact value of the lifetime is not known at time O but is known to be greater than or equal
to O. On the other hand, an observation of the lifetime is said to be left censored at time O if the exact
value of the lifetime is not known at time O but is known to be less than or equal to O. Right censoring is
common in lifetime data analysis. If patients are still alive at the time of observation then their lifetimes are
right censored. Left censoring usually occurs if observation does not start immediately and some individuals
have already died before the observation starts.
Suppose there are n individuals, such that the ith individual’s lifetime Ti is observed only if Ti ≤ Oi, i =
1, ..., n. Therefore, Oi may be the censoring time for individual i, and we call it a potential censoring time if
it is considered without regards to whether censoring or death occurs. Let us consider the continuous lifetime
distribution case and suppose that the censoring times O1, .., On are fixed. We also assume that the Ti are
independent and identically distributed with the density function f(t) and survival function S(t). Then, for
individual i, we can only observe
ti = min(Ti, Oi),
and the indicator function
δi =
 1 if Ti ≤ Oi,0 if Ti > Oi,
where δi = 1 indicates that death is observed, and δi = 0 indicates that censoring occurs.
Note that ti is a mixed random variable with a continuous and a discrete component, and δi is a discrete
random variable. The joint density function of ti and δi can be expressed as
f(ti)
δiS(Oi)
1−δi .
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If the pairs (ti, δi) are independent, the likelihood function becomes
L =
n∏
i=1
f(ti)
δiS(Oi)
1−δi .
Based on our prototypical example, we assume the lifetime distribution is an exponential distribution. In
this case,
S(t) = e−θt
and
L = θre−θ(
∑n
i=1 ti)
where r =
∑n
i=1 δi is the total observed number of deaths, and
∑n
i=1 ti is the total observed lifetime.
1.7 A brief summary
Through the above general introduction, we have constructed a prototypical example, and specified assump-
tions for this example. We also reviewed relevant background information in the areas of clinical trials,
randomization, sequential method and lifetime data analysis. These build the foundation of our dissertation
and the more detailed discussion in the following chapters. In Chapter 2, we will discuss the basic ingredients
of general Bayesian approach for clinical trials. This includes fundamental elements, Bayesian approach, and
adaptivity applied in clinical trials. All of these are useful for later studies. In Chapter 3, we will discuss
the sequential selection of treatment with delayed response, and will give a full detailed formula on a special
controlled stochastic processes. We will derive the optimality equations of the bandit process and will list
the theoretical properties. In Chapter 4, we will focus on detailed results and from that derive the optimality
equations in a prototypical example. Finally, we will present our conclusions and discuss prospects for future
research.
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Chapter 2
Bayesian approach for clinical trials
In this chapter, we progressively provide an overview of Bayesian modelling and inference, to explain
why the Bayesian approach is important in clinical trials, and how it works to support our special controlled
stochastic processes. Typically, the frequentist is the standard statistical approach to designing and analyzing
in clinical trials. However depending on the primary purpose, we focus on an alternative approach called
the Bayesian approach, which began with a posthumous publication in 1763 by Thomas Bayes, an English
clergyman who lived from 1702 to 1761.
2.1 Bayesian approach
We define a Bayesian approach as the explicit quantitative use of external evidence in the design, moni-
toring, analysis, interpretation and reporting of a clinical trial[34]. Such a perspective can be more flexible
than traditional methods in that it can adapt to each unique situation, more efficient in using all available
evidence, more useful in providing predictions and inputs for making decisions for specific patients, for plan-
ning research or for public policy, and more ethical in both clarifying the basis for randomization and fully
exploiting the experience provided by past patients.
Generally, the Bayesian approach has two major advantages[8]. Firstly, experiments can be altered in
midcourse, disparate sources of information can be combined, and expert opinion can play a role in inferences.
Secondly, the Bayesian approach can be decision-oriented, with experimental designs tailored to maximize
objective functions, such as overall public health benefit. So the basic idea of Bayesian approach in clinical
trials is reasonably straightforward. In the next section, we will discuss the fundamental elements used in
Bayesian approach.
2.2 Fundamental elements
In frequentist statistics the observation y is random, with a density or probability mass function given by
f(y; θ), and the parameter θ is treated as a fixed unknown value. On the other hand, in Bayesian statis-
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tics y and θ are both regarded as random variables, with joint density given by pi(θ)f(y; θ), where pi is the
prior density on θ. By modelling both the observed data and any unobserved data as random variables, the
Bayesian approach to statistical analysis provides a complex model with external knowledge, expert opinion,
or both. Before we introduce the technical details of the Bayesian approach we will first discuss some details
of likelihood, prior distribution and posterior distribution, which play a central role in the arguments of this
dissertation. The key conceptual point is the way that the prior distribution on the unknown parameter θ is
updated, on observing the realized value of the data y, to the posterior distribution, via Bayes’ law.
2.2.1 The likelihood function
The likelihood function of a set of parameters θ given some observed values y is equal to the probability
density function of those observed values given those parameter values, the function associates the values
f(y; θ) to each θ. The likelihood function is denoted by L(θ; y). We mostly work with its logarithm l(θ; y),
often abbreviated to l(θ). The log form is due to convenience, in particular because the likelihood function
will often be a product of component terms. Occasionally we work directly with the likelihood function
itself. By using a particular value θ, the larger the value of L the greater are the chances associated to the
observation under consideration. Therefore, by fixing the observed values y and varying parameter θ, we can
observe the likelihood value of each θ. This is sometimes elevated into a principle called the likelihood principle.
The likelihood function leads to the likelihood principle, which states that by making inferences or deci-
sions about θ after y is observed, all relevant experimental information is contained in the likelihood function
for the observed y. This principle draws a clear line that separates the inference schools. On one side,
the Bayesian and likelihood approaches do not violate this principle, and on the other side the frequentist
approach is based on the probabilities implied by the sampling distribution of y.
2.2.2 The prior distribution
In a Bayesian analysis, prior information about a parameter θ is assessed as a probability distribution on θ.
This distribution depends on the assessor and can be calculated any time when the assessor has a precise
enough opinion. Since posterior distributions depend on prior distributions, we can use prior distributions to
drive Bayesian analysis at any time when the assessor has an opinion and therefore it influences conclusions.
When a person’s opinion about a parameter includes a broad range of parameter possibilities, a diffuse prior
distribution may be chosen. In some cases a prior distribution is so diffuse that it does not integrate to 1,
which we call an improper prior. In other cases, opinions may allow for only a few values of the parameter.
And the most extreme case would be a prior that places all its mass on one value.
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A typical prior distribution for which it is simple to assess influence is named conjugate prior. When a
conjugate prior distribution is available, conjugate prior property can be used to obtain a posterior density of
the same form as prior density but with different parameters. When this happens, the common parametric
form of the prior and posterior is called a conjugate prior family. Conjugate families are very convenient and
allow a variety of shapes wide enough to capture our prior beliefs. There is no universal law that says we
must use a conjugate prior. In non-conjugate cases the posterior distribution must be computed numerically.
Therefore, in cases where we can find a conjugate family, it is very common to use it. We will give a detailed
example combined with Bayes’ theroem in the next section.
2.2.3 Bayes’ Theorem
Bayes’ theorem is the basic tool of Bayesian analysis. To specifying a likelihood distributional model f(y | θ)
for the observed data y = (y1, ..., yn) given a vector of unknown parameters θ = (θ1, ..., θk), suppose that θ
is a random quantity sampled from a prior distribution pi(θ | λ), where λ is a vector of hyper-parameters.
The prior distribution tells us how to update beliefs based upon observations. To update beliefs about an
unknown parameter θ, Bayes’ theorem is used to calculate the posterior probability of the unknown param-
eter. If λ is known, inference concerning θ is based on its posterior distribution,
p(θ | y, λ) = p(y, θ | λ)
p(y | λ) =
p(y, θ | λ)∫
p(y, θ | λ) dθ =
f(y | θ)pi(θ | λ)∫
f(y | θ)pi(θ | λ) dθ . (2.1)
Since, in practice, λ will not be known, a hyperprior distribution h(λ) will be required in this approach,
and (2.1) will be replaced with
p(θ | y) = p(y, θ)
p(y)
=
∫
f(y | θ)pi(θ | λ)h(λ) dλ∫∫
f(y | θ)pi(θ | λ)h(λ)dθdλ. (2.2)
This multi-stage approach is called hierarchical modelling, a subject to which I will give more details in
the next section. Rewriting Bayes’ theorem: “posterior probability ∝ likelihood × prior probability”,
where ∝ means proportional to. Again, Bayes’ theorem provides a formalism for learning clinical trials:
the prior represents the previous patients’ historical information what was thought before seeing the next
patient’s data, the likelihood represents the patients’ data now available, and the posterior represents what is
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thought given both prior information and the data just observed. Continual and instantaneous updating can
occur as today’s posterior becomes tomorrow’s prior. To better understand this process, we use an example
to explain it.
Example 2.1 :
Suppose we have observed a normal distribution Y ∼ N(θ, σ2) with σ2 known, so that the likelihood L(y|θ) =
1
σ
√
2pi
exp(− (y−θ)22σ2 ), y ∈ R, θ ∈ R, and θ2 > 0. If we specify the prior distribution as pi(θ) = N(θ|u, τ2), then
from (2.1) we can get the posterior as
p(θ|y) = N(θ|u, τ
2)N(y|θ, σ2)
p(y)
= N
(
σ2
σ2 + τ2
u+
τ2
σ2 + τ2
y,
σ2τ2
σ2 + τ2
)
.
Consider the more realistic case where the sample variance σ2 is unknown. And let h = 1/σ2 have a
Gamma(a, β) prior with probability density function
p(h) =
βa
Γ(a)
ha−1e−hβ , h > 0.
Since the likelihood for any one observation yi is still
f(yi|θ, h) = h
1/2
√
2pi
e−
h
2 (yi−θ)2 ,
the posterior of h is proportional to the product of the full likelihood and the prior,
p(h|y, θ) ∝
[
n∏
i=1
f(yi|θ, h)
]
× p(h)
∝ hn2 e−h/2
n∑
i=1
(yi − θ)2 × ha−1e−hβ
∝ hn2 +a−1e−h[β+ 12
∑n
i=1(yi−θ)2],
where in all three steps we have absorbed any multiplicative terms that do not involve h into the unknown
normalizing constant. Looking again at the form of the gamma prior in
p(h) =
βa
Γ(a)
ha−1e−hβ , h > 0.
We recognize this form as proportional to another gamma distribution, namely a
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Gamma
(
n/2 + a, β +
1
2
n∑
i=1
(yi − θ)2
)
,
where the θ is known.
Thus, the posterior for h is available via conjugacy, and it turns out the gamma distribution offers a conjugate
prior.
After a brief overview of fundamental elements, we can make a clear idea to get the posterior distribution,
and build the Bayesian modelling. More detail about Bayesian model will be presented in the next chapter.
2.3 Adaptivity in clinical trials
A fully Bayesian approach uses the likelihood function, the prior distribution, and a utility structure to ar-
rive at a decision. The prior distribution is used to summarize all available information of model parameters
before the data is observed. It is combined with the likelihood function using Bayes’ Theorem to obtain
the posterior distribution. A loss function assigns numerical values to the various gains and losses that
are obtained from unknown parameters. It essentially determines how to weigh outcomes and procedures.
Bayesian statistical decision theory suggests choosing procedures that have high utility when averaged with
respect to the posterior.
The fully Bayesian approach is insufficient in everyday practice[8]. Firstly, in a regular trials, there are
often multiple decision makers, all of whom have their own prior opinions. Secondly, since the data arrive
sequentially over time, at each monitoring point decision makers should use backward induction(a process
of reasoning backwards in time, from the end of a situation to determine a sequence of optimal actions.) to
check whether to stop or continue the trial, account the information for the next observation, and the cost
of obtaining them. Thirdly, the eliciting costs and benefits are hard to calculate in the process. Moreover,
it seems somewhat arbitrary that the appropriate scales of losses are hard to work with and lead to decision
rules. For the above reasons, fully Bayesian approaches have largely failed to gain a foothold in regulatory
work.
In a clinical trial, when matters turn to experimental design, the Bayesian approach is somewhat less
controversial. This is because in order to carry out a sample size calculation, the designer must have some
prior information regarding the likely effect of the treatment and its variability. More formally, all evaluations
at the design stage are integrating over uncertainty in both samples and parameters. In the terminology of
Rubin(1984), this double integration is a “Bayesianly justifiable frequentist calculation[29]”. More informa-
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tion about this can be found in “Bayesian Adaptive Methods for Clinical Trials”[37].
Our purpose in this dissertation is to construct a bandit process using the full Bayesian approach to test
censored lifetime in clinical trials. In this chapter we have introduced the basic Bayesian approach to support
our model. In the following chapter we will start to discuss a special controlled stochastic process named
bandit process with delayed response.
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Chapter 3
Bandit process with delayed response
3.1 Introduction
Motivated by our purpose and the prototypical example, we will use a bandit process with delayed response
to construct our model in this chapter. A multi-armed bandit process is a sequential experiment with the
goal of achieving the largest possible reward from a payoff distribution with unknown parameters[36]. Typ-
ically, a k-armed bandit process considers sequential selections from k ≥ 1 stochastic processes. In the past
decade, bandit process have been briefly mentioned as a possible design of clinical trials. In clinical trials,
arms usually represents the treatments, and selecting an arm means assigning a treatment to the patient.
Selections among the arms are specified by strategy, which is a criterion for selection of treatments. A strat-
egy is called optimal if it maximizes the expected payoff. In a bandit process, the core content is getting
the largest possible reward. The objective from a selection is usually defined as an expected value of the
response variable, and considered as the expected value of the patients’ residual lifetime in a clinical trial.
Based on reward, the worth of a strategy is an expected value of all rewards averaging over all possible selec-
tions resulting from the strategy. In addition, for the purpose of guaranteeing the finiteness of the expected
value from a possibly infinite horizon model, i.e, more patients more wait for present patient. We define a
discrete discount sequence D = (a1, a2, ...) on future patients, such that an ≥ 0 and ∞∑
n=1
an < ∞. Denote
Dn = (a1, a2, ..., an, 0, 0, ...), D
m = (am, am+1, ...) and D
m
n = (am, ..., an, 0, 0, ...),m ≤ n. If an = βn−1 for all
n and some β ∈ (0, 1), we say that D = (a0, a1, a2, ...) is a geometric sequence and we will set the uniform
sequence Dn = (a1 = 1, a2 = 1, ..., an = 1, 0, 0, ...) in our prototypical example to make the calculation quick
and easy. More comprehensive discussions on determining the sequence of factors can be found in Berry and
Fristedt[3].
In our model, we will follow the Bayesian approach to employ a Markov decision process. The Markov
decision process is a framework for modelling decision making in situations where outcomes are partly ran-
dom and partly under the control of a decision maker. This process is necessary and sufficient for selecting
the arms in each strategy. Because the patient feedback is not immediate, all updated information in our
model have a delayed response and a lag time is defined for this possibility of delayed responses. If the bandit
process has a delayed response, the underlying stochastic process is no longer a Markov process because
the future behaviour depends not only on the posterior distribution but also on delayed responses. But if
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the responses follow loss-of-memory distributions (like geometric distribution or exponential distribution),
the formulated controlled stochastic process becomes a Markov decision process[44]. Corresponding to our
prototypical example, we assume that at the beginning time T1 = 0, there is a prior distribution G1, which
is a gamma distribution g(η1, τ1) for the hazard rate θ of the unknown treatment. Based on G1, we start
to observe the first patient’s lifetime Xi1 , where the arm i1 is selected. After a lag time y1 = Y1(ω), the
second patient enters the experiment, then we get the possibly censored observation (Zi1 , Ii1), where I is
indicate function. It is applied to update G1 to a posterior distribution G2 at the time y1 using the Bayes’
theorem. Then it follows the conjugate family distribution properties, the distribution G2 is still a gamma
distribution, with the parameters (η2, τ2) and provides new knowledge about the randomness of the arms...
Based on G2, we select a new arm i2 arrival at second patient which called stage 2, and start to observe
Xi2 . The posterior G2 is now the prior for stage 2 and we continue to observe Xi1 if the indicator function
Ii1 = 0. After another delay time y2 at stage 3, we update the posterior distribution G3, and select an arm
again. Finally, this process of selections is repeated at a sequence of selection time points, and the controlled
stochastic processes becomes a Markov decision process.
This chapter is organized as follows: we first introduce some basic definitions of bandit process, then we
formulate the model and indicate the objectives, and finally we derive the optimality equations and optimal-
ity strategies. Our objective of this chapter is to construct our model and to derive an optimal strategy.
3.2 Arms, censoring times and censored observations
In our model, the arm can be consider as a sequence of random variables on a probability space (Ω, F ). The
arm i consists of a sequence of random response variables {X(i,n);n = 1, 2, ...}, which represents n patients’
residual lifetime after treatment i. The response variable X(i,n) is survival time after some treatment i, and
it can be observed at any time after the selection. Since all treatments are allocated at the patients’ random
arrival times, the arm selection should be made at random selection times. Hence, we define a sequence of
selection times {Tn;n = 1, 2, ...} as T1 = 0, T2 = Y1 + T1, T3 = Y2 + T2,..., Tn = Yn−1 + Tn−1, where Ti
represent arrival times of patients and {Yn;n = 1, 2, ...} is the sequence of inter arrival times or lag times.
Suppose that only one arm can be selected for observation at each stage. If arm i is selected at stage n, and
there is a lag time Yn before the next stage occurs, then the possibly censored observation of response variable
at the next stage n+ 1 is {Zin,n+1, I{X(i,n)≤Yn}}, which consists of censored lifetime Zin,n+1 = min(X(i,n), Yn)
and its indicator function
I{X(i,n)≤Yn} =
 1 if X(i,n) ≤ Yn0 otherwise.
If the indicator function I{X(i,n)≤Yn} = 0, i.e., during that lag time Yn, we have a censored observation of
X(i,n) at stage n+ 1 and we only can get incomplete information on arm i from X(i,n), and the nth patient is
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still living. Otherwise, if I{X(i,n)≤Yn} = 1 indicates that complete observation of X(i,n) is available at stage
n + 1, and the nth patient was dead. Extending to the general case, for any m ≥ n, the possibly censored
observation {Zin,m, I{X(i,n)≤Tm−Tn}} of X(i,n) at stage m consists of the possibly censored lifetime Zin,m =
min(X(i,n), Tm − Tn) and its indicator function
I{X(i,n)≤Tm−Tn} =
 1 if X(i,n) ≤ Tm − Tn0 otherwise.
Example 3.1 :
For the prototypical example, to model the censoring of the patients’s lifetime we assume that Xi,n follows the
exponential distribution with unknown parameter θ and Yn follows the exponential distribution with known
parameter σ. The parameter 1σ indicates the average inter-selection times between consecutive selections,
and the number of selections occurring in a fixed time interval (0,T ), which has a Poisson distribution with
parameter σT . Then we can find that the (n+ 1)st selection time Tn+1, n ≥ 1, has a gamma(n, σ) distribu-
tion. Conditional on θ, the possibly censored observation Zin,n+1 has the distribution P (Z
i
n,n+1 ≤ x|θ) = 1
− e−(θ+σ)x, and the indicator function I{Xi,n≤Yn} is a Bernoulli random variable with the parameter θθ+σ as
the probability of success.
Up to here all fundamental elements in the model have been defined, and in the later subsection we shall
use them to apply the Bayesian approach.
3.3 The states and transition
Following the Bayesian approach, we can define a dynamic stochastic model, which can completely describe
the randomness of the arms at the corresponding stages, and can indirectly describe the effectiveness of
the treatments in clinical trials. It is very clear that the prior and posterior distributions play a key role
in describing the state of our controlled processes. West and Harrison[41] have shown that a condition to
describe the dynamic model that is the current state must depend on previous states and observations. Since
a posterior distribution depends on the prior distribution, and the observations are in controlled stochastic
processes, we are really interested to know whether this dependence is measurable in our model.
In order to achieve the dynamic model, we discuss states and transition in this subsection. They play
the key role in the dynamic and randomness models. We denote the information bank by (Ci,n, (Z
i
(j),n, j =
1, ..., Ci,n)), Ci,n is the patient on the unknow arm who are still living. It can completely describe the
censored information on arm i at stage n. The size of the information bank Ci,n is the total number of
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censored observations on arm i at stage n. Zi(1),n, ..., Z
i
(Ci,n),n
are the censored observations on arm i at stage
n, that represent the lifetimes of individuals who are still alive at a time before the decision on the next
patient is made. If Ci,n = 0, then the information bank is empty and all lifetimes on arm i are uncensored
at stage n. If there are k-armed selections, the posterior distribution is denote by Gn, and the random tuple
sn = [Gn, (Ci,n, Z
i
(j),n, i = 1, ..., k, j = 1, ..., Ci,n)]
completely describes the state of process with censored observations at stage n, and provides sufficient in-
formation for selecting an arm. Let S be the set of all such possible states sn, and call it the state space.
Following the state space and the action space, we can describe any transition of the process from one stage
to another. Since arm i can be chosen randomly in the action space, and the censoring time yn is the realized
value of random variable Yn, then the state sn+1 is random. This randomness can be described by the state
transition probabilities. Wang[40] denotes a transition probability Qn+1(sn+1 ∈ H|sn, in, yn) in a conditional
probability distribution as the probability that the state sn+1 at stage n + 1 is in the measurable subset H
of state space S, given the state sn, selection in and value yn. Depending on the different treatments, there
are many cases for the new transition probability, and this is another randomness to be applied. Here we use
an example to make it more clear.
Example 3.2 :
For the prototypical example, consider one patient’s case. Since our payoff distribution have a prior gamma
distribution g(ηn, τn) with hazard rate θ, which has the loss of memory property, we can simply write the
state of treatment sn = ((ηn, τn), (cn)), where cn is the total number of censored observations at stage n.
Suppose the state at stage one is given as s1 = ((η, τ), (0)) and selected treatment is i1, and the observation
is y. Then the state at stage two is s2 = ((η2, τ2), (c2)). Since the censoring times are continuous, we can
denote a transition probability Q2(s2 ∈ H|s1, i1, y) by a conditional probability of a measurable subset H of
state space at stage 2. Depending on the treatment we selected initially, there are three cases for the new
transition probability.
If the known treatment B at the first patient, i.e., i1 = 2 then all the expected lifetimes λ are known, and
the observation of its lifetime provides no information on treatment A, i.e., the information bank is empty
and together with the initially number of censored observations c1 = 0, i.e, data bank empty. That is to say,
the state will be the same as the state at the first stage, even if there are some censoring times y.
On the other hand, if the unknown treatment A is selected initially andG1 is the gamma (η, τ) distribution,
19
for any t > 0, the lifetime X under the state s1 has a probability density function :
P (X ≤ t) = E(I{X≤t})
= E(E(I{X≤t})|θ)
=
∫ ∞
0
∫ t
0
θe−θsds
ητ
Γ(τ)
θτ−1e−ηθdθ
=
∫ ∞
0
(1− e−θt) η
τ
Γ(τ)
θτ−1e−ηθdθ
= 1−
(
η
η + t
)τ
.
The marginal density function of X:
f(t) = τητ
(
1
τ + t
)τ+1
.
Let Z = min(X, y) and δ = I{X≤y}, because of gamma distribution is conjugate distribution then the state
s2 is of the form:
s2 = ((η + Z, τ + δ), (1− δ)).
If the censored patient still alive after censoring time y(i.e. δ = 0) :
B2(y) = {((η + y, τ), (1))}
If the censored patient died during the censoring time y :
B3(x, y) = {((η + x′, τ + 1), (0)) : 0 ≤ x′ ≤ x ≤ y},
where x′ is the time between last arrival and death.
Then for any y and any 0 ≤ x ≤ y, B2(y) and B3(x, y) are measurable subsets of S. We have
Q2(s2 ∈ B2(y)|s1, i1 = 1, y) = P1(X ≥ y|s1, i1 = 1, y) =
(
η
η + y
)τ
.
And for any 0 ≤ x ≤ y,
Q2(s2 ∈ B3(x, y)|s1, i1 = 1, y) = P1(0 ≤ X ≤ x|s1, i1 = 1, y)
= 1−
(
η
η + x
)τ
.
So s2 is of mixed type, whose probability is (
η
η+y )
τ at one-point mass ((η + y, τ), (1)) and whose density is
τητ ( 1τ+t )
τ+1. on the interval [0, y].
In this subsection, we have described the dynamics of a stochastic system. In the terminology of con-
trolled stochastic processes, selecting an arm means taking an action. In our model, the action space is
A = {1, ..., k}, so the selections are made among the k arms at various stages, and are specified by strategies.
In the next subsection, we will discuss some details of strategies and their worths.
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3.3.1 The strategies and their worths
In our model, a strategy is just a sequence of measurable functions, denote by pin : S ×An−1 → A.
Define a reward r(s, i, t), which is the expected value of the random lifetime Xi,n from selecting arm i
when state is s at time t. That is,
r(s, i, t) = E(Xi,n|G) =
∫
Dk
∫ ∞
0
xdFi(x)dG(F1, ..., Fk),
where G is a posterior distribution on (F1, ..., Fk) that depends on t.
Following this structure we can define the worth of any strategy. Recall that F0 is the distribution for the
sequence of potential censoring times, and its nth convolution F
(n)
0 is the distribution of the (n+1)th selection
time Tn+1, n = 1, 2, .... The first selection occurs at time T1 = 0, so we denote F
(0)
0 to be the discrete one-
point distribution such that F
(0)
0 (x) = 1 for all x ≥ 0. For each n = 1, 2, ... let Dn : R+ → R+ be a discount
function for the nth selection, such that
∞∑
n=1
∞∫
0
Dn(t)dF
(n−1)
0 (t) <∞. Consider that each strategy pi specifies
a sequence of selections of the arms {in, n = 1, 2, ...} and develops a sequence of states {sn, n = 1, 2, ...}.
Therefore the strategy pi generates a process {(sn, in) : n = 1, 2, ...} in the space
∞×
0
(S × A). By Kol-
mogorov’s existence theorem[22], we can define a probability measure Ppi on
∞×
0
(S × A × R+). So let Epi
be the expectation taken with respect to Ppi, and denote by X(in,n) the survival time generated by strategy
pii at stage n, which has the arrival time distribution F
(n−1)
0 (t), and denote Zn(t) the censored survival time
distribution of nth patient which depend on time t.
Now we can define the finite horizon worth with N selected patiens of the strategy pi to be
WN (s1, pi) =Epi
 N∑
n=1
∞∫
0
Dn(t)Zn(t)dF
(n−1)
0 (t)

=
N∑
n=1
∞∫
0
Dn(t)[EpiZn(t)]dF
(n−1)
0 (t);
Example 3.3 :
For the prototypical example, since the known treatment B gives known expected lifetime λ, then for any
state s, and any time t, if i = 2 then r(s, i, t) = λ. On the other hand, since the effectiveness of treatment A
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is unknown, s is of the form ((η, τ), (c)), then r is continuous in η, τ ; and it is of the form
r(s, i, t) =E(X(1,n)|(η, τ))
=
∫ ∞
0
∫ ∞
0
xθe−θxdx
ητ
Γ(τ)
θτ−1e−ηθdθ
=
∫ ∞
0
1
θ
ητ
Γ(τ)
θτ−1e−ηθdθ
=
∫ ∞
0
ητ
Γ(τ)
θ(τ−1)−1e−ηθdθ
=
η
τ − 1
∫ ∞
0
ητ−1
Γ(τ − 1)θ
(τ−1)−1e−ηθdθ
=
η
τ − 1
.
Let us consider the worths of four non-adaptive strategies pi1, pi2, pi3, pi4, all with the initial state s1 =
((η, τ), (0)) and let D = (a1, a2, ...) be a discount sequence.
Suppose pi1 chooses the treatment A at both stages, and stage two occurs after a delay time t. If the first
patient has died at time x ≤ t, then the state at stage two is s′2 = ((η + x, τ + 1), (0)) and the the expected
lifetime of second patient is r(s′2, i2 = 1, t) =
η+x
τ . On the other hand, if the first patient is still alive at
time t, then the state at stage two is s′′2 = ((η + t, τ), (1)), and the the expected lifetime of second patient is
r(s′′2 , i2 = 1, t) =
η+t
τ−1 .
Therefore,
Epi1Z2(t) =
t∫
0
r(s′2, 1, t)τη
τ
(
1
η + x
)τ+1
dx+
∞∫
t
r(s′′2 , 1, t)τη
τ
(
1
η + x
)τ+1
dx
=
t∫
0
η + x
τ
τητ
(
1
η + x
)τ+1
dx+
∞∫
t
η + t
τ − 1τη
τ
(
1
η + x
)τ+1
dx
=
η
τ − 1
Finally, we get the worth:
W2(s1, pi1) =a1
η
τ − 1 + a2
∞∫
0
β2(t)
η
τ − 1σe
−σtdt
=a1
η
τ − 1 + a2
∞∫
0
e−at
η
τ − 1σe
−σtdt
=a1
η
τ − 1 + a2
σ
σ + a
η
τ − 1 .
Suppose pi2 chooses treatment B at both states then the worth is
W2(s1, pi2) = a1λ+ a2
σ
σ + a
λ.
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Suppose pi3 chooses treatment A at first stage, and treatment B at second stage then the worth is
W2(s1, pi3) = a1
η
τ − 1 + a2
σ
σ + a
λ.
Suppose pi4 chooses treatment B at first stage, and treatment A at second stage then the worth is
W2(s1, pi4) = a1λ+ a2
σ
σ + a
η
τ − 1 .
Up to here, we defined strategies and their worth equations. We are interested in the optimal strategies and
the best worth equation of our model. This will be the topic of the following subsection.
3.4 Optimality equations and optimal strategies
In our model, the optimality equations are a sequence of functional equations which not only embody the
principle of dynamic programming, and depict the recursive relations between the values of the bandit pro-
cesses of various horizons, but also, and more importantly, lay a foundation for calculating the value and
finding an optimal strategy in principle[40].
For any given m = 1, 2, ..., we suppose that stage m occurs at a given random time T , and the given state
sm has the posterior distribution Gm, which depends on tm. Consider a strategy pi that selects arm i at stage
m and follows an optimal strategy from m+ 1, where the immediate expected reward is Dm(tm)r(sm, i, tm).
Then we denote a value of optimal strategy:
V (m, sm) = sup
pi
W (m, sm, pi)
= sup
pi
k∑
i=1
pim({i}|sm, i1, ..., im − 1)
Dm(tm)r(sm, i, tm) + ∞∫
0
∫
S
V (m+ 1, s)Qm+1(ds|sm, i, t)dF0(t)
 .
The right hand side without the sup is the worth of the strategy pi from stage m on. The value of this
strategy from stage m + 1 is V (m + 1, sm+1), which depends on the state sm+1 at stage m + 1 under this
strategy. Since this strategy presents in principle the value of the bandit process from stage m + 1 on, the
value of the bandit process should be the sup over all such strategies.
Optimality equations play an essential role in any dynamic programming model. We hope to find an
optimal strategy, but the arms are chosen in a random way so the set of all strategies is uncountable. How do
we avoid the uncountable? The best method is try to restrict the randomized strategy to a non-randomized
strategy. Due to Wang’s Theorem 2.4.1, for any randomized strategy, there is a non-randomized strategy
which dominates the randomized strategy. Hence, depending on our model suppose there exists an optimal
strategy. It must be one which is non-randomized, then we can restrict ourselves to the set of all non-
randomized strategies to find an optimal strategy. In order to prove the existence of an optimal strategy, we
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reduced the optimality equations to simpler forms:
V (m, sm) =
k∑
i=1
Dm(tm)r(sm, i, tm) + ∞∫
0
∫
S
V (m+ 1, s)Qm+1(ds|sm, i, t)dF0(t)
 .
We can use this simpler form, combined with Theorem 2.5.1 in Berry and Fristedt[3] to give the follow-
ing result. For any state sn ∈ S, there must exist a non-randomized strategy pi∗ which is optimal, i.e.,
V (sn) = W (sn, pi
∗). To prove this theorem, we can start with horizon models first, then test for the general
infinite horizon processes. Wang provides a detailed proof in section 2.5 of his thesis[40], so we do not list
here again.
For the motivated example, since an optimal strategy can be found in the set of all non-randomized
strategies, so we put the focus on the worth W (pi) of a non-randomized strategy pi. There are many questions
of the properties of W (pi) should be discussed, first is whether W (pi) depends continuously on the parameters
(η, τ); second is how to order the relations among parameters affects the values of W (pi). Before test these
properties, we first examine the structure of the worth W (pi) on any strategy pi.
3.4.1 The structure of the worth
Let us write u = ητ , then the hazard rate θ has expected value E(θ) =
τ
η = u
−1. Suppose the unknown
treatment has expected hazard u−1, while the known treatment has constant hazard λ−1. As shown at
the past sections, the marginal density of lifetime T on the unknown treatment is f(t) = τητ ( 1η+τ )
τ+1, the
marginal distribution is F (t) = 1 − ( ηη+τ )τ , and the expected value of lifetime is ητ−1 . Suppose the trial
starts at time 0, with Gamma (η, τ) prior distribution. And at any time t, we observed a total lifetime T
which does not matter censored or uncensored, and a total number r of deaths on the unknown arm, then
the posterior at time t is also a Gamma distribution with parameter (η + T, τ + r). Since the lifetimes
follow an exponential distribution, which has the loss of memory property, the state at any stage n is of
the form sn = ((ηn, τn), (cn)). The observations at the next stage n + 1 only depend on state sn, and se-
lection in made at stage n, as well as the potential censoring time yn between the n
th and (n+1)th selections.
Suppose that at some stage, the state is s = ((η, τ), (c)), let T ′1, ..., T
′
c be the residual lifetimes for these c
patients’ censored lifetimes, and the next stage occurs at a random lag time Y later. Then the observations of
these residual lifetimes at the next stage are Zi = min(T
′
i , Y ), and their indicator functions are ρi = I{T ′i<Y }.
Since there is only need to consider non-randomized strategies, consider pi to be the set of all non-randomized
strategies, and pi1 (pi2 respectively) to be the subset of pi consisting of strategies which select the unknown
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(known respectively) arm initially. Let N be any positive integer. Recall that
WN (sm, pi) = Epi
 N∑
n=m
∞∫
0
Dn(t)Zn(t)dF
(n−m)
0 (t)

is the worth of the strategy pi from stage m to N , m ≤ N .
We now discuss the recursive equations for the worths of myopic strategies with various horizons. A
myopic strategy is the one that maximizes the reward for the current patient. In our model, the myopic
strategy is very important for simulations and can be considered as using the best treatment for the patient
currently.
First suppose pi2 ≥ pi1, i.e., the known treatment is better than the unknown treatment, and the known
arm is selected initially. In addition, all future selections will also be the known arm if the first arm selected is
the known treatment. For any given value l, there are
 c
l
 possible ways to select l deaths from c lifetimes.
Since all lifetimes are independent and identically distributed , without loss of generality, let t1, ..., tl, be l
uncensored observations. Then,
∫∞
y
f(t)dt = q(y) =
(
η
η+y
)τ
for censored lifetimes, and min(Ti, y) = Ti for
uncensored lifetimes Ti, we have
WN (s, pi2) = a1
η
τ − 1 + Epi2
(
WN (2, s
(2), pi2)
)
= a1
η
τ − 1 +
c∑
l=0
 c
l
 ∞∫
0
y∫
0
...
y∫
0︸ ︷︷ ︸
l
WN (2, s
(2), pi2)f(t1)...f(tl)dt1...dtl[q(y)]
c−lσe−(σ+a)ydy,
s(2) =
(
(η(2), τ (2)), c(2)
)
,
η(2) = η +
c∑
i=1
Zi = η +
l∑
i=1
ti + (c− l)y,
τ (2) = τ +
c∑
i=1
ρi = τ + l,
c(2) = c−
c∑
i=1
ρi = c− l.
On the other hand, suppose pi1 > pi2, i.e., the unknown arm is selected initially. Let Tc+1 be the random
lifetime from this new selection. Then its observations at the next stage consists of Zc+1 = min(Tc+1, Y ) and
ρc+1 = I{Tc+1≤Y }. The state at the next stage is random, and for the strategy pi1 we have
WN (s, pi1) = a1
η
τ − 1 + Epi1
(
WN (2, s
(1), pi1)
)
= a1
η
τ − 1 +
c+1∑
l=0
 c+ 1
l
 ∞∫
0
y∫
0
...
y∫
0︸ ︷︷ ︸
l
WN (2, s
(1), pi1)f(t1)...f(tl)dt1...dtl[q(y)]
c+1−lσe−(σ+a)ydy,
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where q(y) =
(
η
η+y
)τ
is the probability of a censored observations at time y, and
s(1) =
(
(η(1), τ (1)), c(1)
)
,
η(1) = η +
c+1∑
i=1
Zi = η +
l∑
i=1
ti + (c+ 1− l)y,
τ (2) = τ +
c+1∑
i=1
ρi = τ + l,
c(1) = c+ 1−
c+1∑
i=1
ρi = c+ 1− l.
Note that both WN (2, s
(1), pi1) and WN (2, s
(2), pi2) have horizon N − 1, so these two equations reduce
the horizon of the worth of any strategy. Now let’s consider how to maximize the total discounted expected
lifetimes when the horizon is 2. That is,
V (s, λ) = suppiEpi
a1Z1 + a2 ∞∫
0
e−ayZ2σe−σydy

= suppiEpi
a1Z1 +
a2 ∞∫
0
e−ayσe−σydy
Z2
 .
If we have immediate responses from the selections, the posterior distribution is the gamma (η + T, τ + 1)
distribution. This is not affected by the particular selection time of the second selection. Therefore, the
expected lifetime for the second selection is always subject to the discount
a2
∞∫
0
σe−(σ+a)ydy = a2
σ
σ + a
.
The worth of strategy pi1 is
W (s, λ, pi1) = a1
η
τ − 1 + a2
σ
σ + a
E
(
η + T
τ
∨ λ
)
,
where
E
(
η + T
τ
∨ λ
)
= λ
[
1−
(
η
η + (a ∨ 0)
)τ]
+
η
τ − 1
(
η
η + (a ∨ 0)
)τ−1
.
Similarly,
W (s, λ, pi2) = a1λ+ a2
σ
σ + a
(
η
τ − 1 ∨ λ
)
.
For comparing the difference between W (s, λ, pi1) and W (s, λ, pi2), there is a simple method. Define
4(s,D) = W (s,D, pi1)−W (s,D, pi2) to be the advantage function of the unknown arm over the known arm.
Then the sign of this function determines an optimal selection of the arm.
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Let u+ = max(u, 0) and v+ = max(v, 0) where u = λτ − η and v = u− λ. Then extending the equation
we get
4(s, λ) =W (s, λ, pi1)−W (s, λ, pi2)
=a1
(
η
τ − 1 − λ
)
+ a2
σ
σ + a
n+∫
m+
(
η
η + y
)τ (
λτ
η + y
− 1
)
e−(σ+a)ydy.
Depending on this equation, we can get the following cases:
1. If η ≥ λτ then u+ = 0, v+ = 0, and
4(s, λ) = a1
(
η
τ − 1 − λ
)
≥ 0.
Therefore, the unknown arm is optimal initially.
2. If λ(τ − 1) ≤ η < λτ , then u+ > 0, v+ > 0,
4(s, λ) = a1
(
η
τ − 1 − λ
)
+ a2
σ
σ + a
λτ−η∫
0
(
η
η + y
)τ [
λτ
η + y
− 1
]
e−(σ+a)ydy ≥ 0,
where y ∈ [0, λτ − η] implies that η + y ∈ [η, λτ ], hence λτη+y − 1 ≥ 0 for all y ∈ [0, λτ − η]. So the unknown
arm is optimal initially.
3. If 0 < η < λ(τ − 1), then u+ > 0, v+ > 0. Because v = λ(τ − 1)− η, we have
4 (s, λ) = a1
(
η
τ − 1 − λ
)
+ a2
σ
σ + a
λτ−η∫
λ(τ−1)−η
(
η
η + y
)τ [
λτ
η + y
− 1
]
e−(σ+a)ydy.
Let η + y = t, then we have
4(s, λ) = a1
(
η
τ − 1 − λ
)
+ a2
σ
σ + a
ητe(σ+a)η
λτ∫
λ(τ−1)
(
1
t
)τ (
λτ
t
− 1
)
e−(σ+a)tdt.
It is clear that 4(s, λ) is a continuous function of η, and for any η ∈ (0, λ(τ − 1)) we have ∂4∂η > 0 and
∂4
∂τ < 0. Hence for any η it is an implicit function of τ for fixed λ, and also an implicit function of λ for
fixed τ , there must exists an η∗ such that 0 < η∗ < λ(τ − 1) and 4(((η∗, τ), 0), λ) = 0. Moreover, if η ≥ η∗
then the unknown arm is optimal; otherwise, the known arm is optimal. And when the other parameters are
fixed, η∗ is an increasing function of τ and λ. So the conclusion is ∃ an η∗ such that the unknown treatment
is optimal if and only λ(τ − 1) ≥ η∗.
So far we have discussed the solution to the motivated example with two selections, and we derived the
critical equation for the case of an empty information bank, which determines the break-even values of η, τ
and λ. In the next subsection we will try to find an optimal strategy pi∗ and find the the value of this optimal
strategy.
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3.4.2 The optimal strategies
Recall that if the initial state of the motivated example is s = ((η, τ), c), and the first selection of the arm is
made at time 0, then the worth of a strategy pi is
W (s,D, pi) = Epi[
∞∑
n=1
∞∫
0
Dn(t)Zn(t)dF
(n−1)
0 (t)],
where F
(n−1)
0 is the distribution of the selection time of stage n,Zn is the random lifetime generated by the
strategy pi at stage n, and Dn = (a1, a2, ...) is the discrete discount sequence. We have also defined the value
of the sequential selection model to be
V (s,D) = sup
pi
W (s,D, pi).
Our objective is to find an optimal strategy pi∗ from
V (s,D) = W (s,D, pi∗).
.
It has been proved that we can restrict our search for an optimal strategy in the set Π of all non-randomized
strategies. Actually, Π = Π1 ∪Π2, where Π1 ∩Π2 = Ø and Π1(Π2 respectively) is the subset of Π consisting
of those strategies which select the unknown (the known respectively) arm initially.
Let φ (ϕ respectively) be a strategy which selects initially the unknown (know) treatment, and then always
selects the known (unknown) treatment at the following stages. Let sφn = ((η
φ
n, τ
φ
n ), c
φ
n) (s
ϕ
n respectively) be
the state generated by the strategy φ (ϕ respectively) when the nth patient is to be treated, and D is a
geometric sequence then we can rewrite
V (sφn, Dn) = 4+(sφn, Dn) +W (sφn, Dn, pi2),
and
V (sϕn, Dn) = 4−(sϕn, Dn) +W (sϕn, Dn, pi1).
In order to show that under some conditions the delta function is increasing in η, and decreasing in τ and
λ, we need to use the following equation[40] which is a continuous analogue of Theorem 2 in Eick[11].
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For any initial state s = ((η, τ), c,D) and λ
4((η, τ), c, λ,D) =
a1 − n∑
j=2
aj
( η
τ − 1 − λ
)
+
n−1∑
j=1
∞∫
0
...
∞∫
0︸ ︷︷ ︸
j
E
[
4+((ηφj , τφj ), cφj , λ,Dj)
]
h(t1)...h(tj)dt1...dtj
−
n−1∑
j=1
∞∫
0
...
∞∫
0︸ ︷︷ ︸
j
E
[4−((ηϕj , τϕj ), cϕj , λ,Dj)]h(t1)...h(tj)dt1...dtj
+
∞∫
0
...
∞∫
0︸ ︷︷ ︸
n
E
[
V ((ηφn, τ
φ
n ), c
φ
n, λ,Dn)
]
h(t1)...h(tn)dt1...dtn
−
∞∫
0
...
∞∫
0︸ ︷︷ ︸
n
E[V ((ηϕn , τ
ϕ
n ), c
ϕ
n, λ,Dn)]h(t1)...h(tn)dt1...dtn.
The reader can find the proof of this in Wang[40].
To see that this delta function determines an optimal initial selection of the arm, Wang has already shown
that 4(s,D) is increasing in η, and decreasing in τ and λ for any D having finite horizon n, but we need to
use a simulation to identify this conclusion again in next section.
In Wang’s simulation, he used Fortran to simulate the experiments but there are some initialization prob-
lem. Fortran is a general-purpose, imperative programming language which is especially suited to numeric
computation and scientific computing. But most of basic programs have not been included in the database,
like the generating random variables which the error occurs in Wang’s simulations.
Up to here, we have introduced all essential definitions and finished the theoretical framework. In the
next chapter, we will try to use a simulation to confirm the properties of the function 4, and give some
conclusions based on the simulation’s result.
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Chapter 4
Simulation and Results
4.1 Introduction
We are now very familiar with the prototypical example as it has been discussed since Chapter 1. In this
chapter, we carry out simulations to analyze the prototypical example. We hope to gain insight into the
structure and obtain some hints for suggesting optimal strategies. Suppose that there is a treatment to be
allocated, and the initial state is s = ((η, τ), c). It has been shown that, when other parameters are fixed,
there exists a unique break-even value η∗N for η, if η ≥ λ(τ − 1). In this case, exactly one of the unknown
arm or known arm is optimal initially. Although this break-even value makes it is easy to define an optimal
strategy, it is hard to find in practice. In the next subsection we discuss in detail what simulations have been
done, and how they are implemented. In section 4.3 we proposed a strategy and compared it with myopic
strategy, then present the results of the simulation and some discussion, including graphs and tables. In
section 4.4 we discuss these results and give some general suggestions for choosing good strategies.
4.2 Simulation
In my simulation, I follow Wang’s method but use a different software environment, and I have corrected an
error on Wang’s algorithm. Wang’s program was designed in Fortran[12], where as my program is written in
R[33]. My simulation also included a wider range of conditions than those found in Wang’s thesis.
The inputs of the simulation are the following:
• the total number of selected patients N ;
• the rate parameter of arrival time distribution σ;
• the constant expected survival time λ on the known treatment;
• the gamma prior distribution g(η, τ) for the hazard rate θ of the unknown treatment;
• the lower bound for searching optimal strategies b∗.
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Generally, we observe the trial for the objective of maximizing the total non-discounted expected lifetimes
from each patient’s finite horizon. There are two sequences of random variates needed. The first sequence
represents the patients’ lifetime, which is exponential inter arrival times generated by the R function rexp.
The second sequence represents the patients’ lifetimes after being treated with either the known or unknown
treatment. As the controlled stochastic process evolves, we observe the arrival time and the lifetimes on the
treatment at any survival time. After we update the state of the controlled stochastic process, we make a
selection of treatment, and generate new lifetimes on treatment. The lifetime is simulated using the true
expected value θ, but the decision of which treatment to apply uses posterior distribution (η, τ). Selecting a
treatment means taking an action from the action space {1, 2}, where if the unknown treatment is selected we
take action 1, and take the action 2 for the known treatment. Suppose that at the time of the nth selection,
the updated state is sn = ((ηn, τn), cn). Under action 1 we generate the cn+1 exponential lifetime by the
parameter θ, and receive a reward ηnτn−1 , while under action 2 we receive a constant reward λ. Then we
generate the arrival time for the next patient, observe these lifetimes, and update the transition of the state
at the next stage. The decision as to which action to take depends on the current state sn = ((ηn, τn), cn), the
number N −n of actions to be taken in the future, and the objective of maximizing the total non-discounted
rewards from all the actions. Denote by pi
(1)
n (and pi
(2)
n respectively) the strategy which selects the unknown
(the known) treatment for the nth patient, and then follows an optimal strategy for the remaining N − n
patients. Denote by WN (n, sn, pi
(1)
n ) and WN (n, sn, pi
(2)
n ) the worths of the N−n+1 patients under these two
strategies pi
(1)
n and pi
(2)
n , respectively. Then the maximum total expected lifetimes from all these N patients
is
VN (s1) = max
(
WN (1, s1, pi
(1)
1 ),WN (1, s1, pi
(2)
1 )
)
, (4.1)
which can be found in principle by the backward induction equations with the initial condition
VN (sN ) = max(
ηN
τN − 1 , λ). (4.2)
To specify an optimal selection of the treatment for the nth patient, we need only to calculate the function
4N (n, sn) = WN (n, sn, pi(1)n )−WN (n, sn, pi(2)n ). (4.3)
Select the unknown treatment optimally for the nth patient if and only if
4N (n, sn) ≥ 0. (4.4)
When n = N we have
4N (sN ) = 4N (N, sN ) = ηN
τN − 1 − λ. (4.5)
In principle, by starting with this equation, and employing the backward induction method of dynamic
programming, we could derive the function 4N (n, sn) for any n. For the simulation code, we use a break-
even value η∗n ∈ (0, λ(τn − 1)) such that 4N (n, s∗n) = 0, where s∗n = ((η∗n, τn), cn). The unknown treatment
is selected at the state sn = ((ηn, τn), cn) if and only if ηn ≥ η∗n. Therefore, we need only to consider those
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strategies defined in the following way. At stage n, choose an ηn ∈ (0, λ(τn − 1)). If the updated state is
sn = ((ηn, τn), cn), then select the unknown treatment if and only if ηn ≥ ηn. So any such point ηn defines
a selection for the nth patient, and we are looking for a point η∗n = ηn which defines the optimal selection.
Since 0 < ηn < λ(τn − 1), let bn = ηnλ(τn−1) . Then bn ∈ (0, 1) and ηn = bnλ(τn − 1). In this case, it is
equivalent to say that any point bn ∈ (0, 1) defines a selection for the nth patient such that the unknown
treatment is selected if and only if ηn ≥ bnλ(τn − 1). Hence, any such strategy pi corresponds to a point
b = (bN , bN−1, ..., b1) ∈ (0, 1)N , and the myopic strategy corresponds to the point (1, 1, ..., 1) ∈ (0, 1)N . The
worth W (pi) of the strategy pi becomes a function q(b) on the space (0, 1)N , and
sup
pi
W (pi) = sup
b∈(0,1)N
q(b). (4.6)
So the search for an optimal strategy becomes finding a point b∗ = (b∗N , ..., b
∗
1) ∈ (0, 1)N such that
q(b∗) = sup
b∈(0,1)N
q(b). (4.7)
We would like to emphasize that b∗n may depend on λ, τn, cn and other parameters from the example. Since
bn could be any number in the range (0,1), this may make the search of b
∗
n difficult, especially true if n is
large. Wang[40] found that b∗ = 0.97 is a good lower bound to search for optimal strategies, so we directly
applied this number to our simulations and tested its accuracy. If the amount of valid information gradually
increased, the myopic strategy will eventually be in a dominant position, that is b∗ = (b∗N , ..., b
∗
1) = (1, 1, ..., 1).
Typically a clinical trial for testing unknown treatment only chooses a small sample and determine whether
to continue the experiment at half of the sample. Hence, we set the myopic strategy must be consistently
better than the proposed strategy when the number of censored observations is over half the number of total
patients. The censored observations in our simulation include the size of information bank c and the number
of died patients τ . Because our simulation focuses on the difference between the proposed strategy and the
myopic strategy, all the values of the result will be omitted if τ > N2 and c >
N
2 . Up to here, we described
the main steps of our simulation and explained the effect of some functions in the program. More details and
the codes can be found in the Appendix. In the next subsection, we will present and analyze some results
which verify and extend Wang’s simulations with a wider selection of parameters.
4.3 Results
Wang has discussed a number of simulations in his dissertation, including the two patients case, three patients
case and fourteen patients case. All of them are used to test the parameters’ properties. In particular, the
fourteen patients case plays a key role in finding the properties of the function 4. Since there are three
main parameters (N, σ, λ) in our simulation, and the function 4 is our main subject of this section, we will
first use the new codes to simulate a fourteen patients case, and compare with Wang’s results. In another
subsection, we discuss the result for other value of the parameters.
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4.3.1 Different selected patients N
In this subsection, we focus on the differences between Wang’s simulation and my simulation. Some of the
initial parameters for simulations have been specified. These include:
• the total number of selected patients N = 14;
• the rate parameter of arrival time distribution σ = 0.5;
• the constant expected lifetime λ = 100 on known treatment;
• a good lower bound b∗ = 0.97 for searching optimal strategies.
We will propose a strategy and compare its performance with the myopic strategy by means of simula-
tions with 10,000 replications. Based on these observations, we can clearly find the difference between two
simulations and answer the question posed in Chapter 3: whether the function 4(s,D) is decreasing as τ
increases for constant N, σ, λ. All tables in this dissertation are mean values over 10,000 simulations. Table
4.1, Table 4.2 and Table 4.3 are copied from Wang’s dissertation. In all tables, the parameter c represents
the size of the information bank, and the parameter τ represents the number of dead patients. The results
only show that the proposed strategy is consistently better than the myopic strategy.
Table 4.1: The value of proposed strategy
based on Wang’s codes, where N=14, σ = 0.5,
λ = 100 and b∗ = 0.97.
τ
c 2 3 4 5 6 7
0 1438.974 1414.461 1406.494 1403.006 1401.410 1400.919
1 1433.865 1413.283 1406.107 1403.012 1402.090 1401.830
2 1429.731 1412.311 1406.076 1403.661 1402.568 1402.536
3 1426.632 1411.380 1406.274 1403.893 1403.306 1403.137
4 1424.389 1410.683 1406.503 1404.260 1403.594 1403.613
5 1422.111 1410.012 1406.323 1404.608 1404.124 1404.093
6 1422.056 1410.458 1406.484 1405.111 1404.652 1404.591
7 1420.643 1410.503 1407.088 1405.581 1405.001 1404.769
Table 4.2: The value of myopic strategy based
on Wang’s codes, whereN=14, σ = 0.5, λ = 100
and b∗ = 0.97.
τ
c 2 3 4 5 6 7
0 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
1 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
2 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
3 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
4 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
5 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
6 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
7 1400.000 1400.000 1400.000 1400.000 1400.000 1400.000
By observing Table 4.2, we find all values in Wang’s myopic strategy are equal to 1400, which is unreason-
able in a mean of simulation with 10,000 replications. There is only one way that can explain this case: all
processes of myopic strategy chose the known treatment for the first patient then subsequent patients have
opted for the same treatment. We trace back to Wang’s program, and discovered that a constant variable
was uninitialized which led the program to assign 0 to this constant variable and defaulted each patient’s
censored lifetime to 100.
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Table 4.3: The advantage value of the proposed
strategy over the myopic strategy based on Wang’s
codes, where N = 14, σ = 0.5, λ = 100 and b∗ =
0.97.
τ
c 2 3 4 5 6 7
0 38.974 14.461 6.494 3.006 1.410 0.919
1 33.865 13.283 6.107 3.012 2.090 1.830
2 29.731 12.311 6.076 3.661 2.568 2.536
3 26.632 11.380 6.274 3.893 3.306 3.137
4 24.389 10.683 6.503 4.260 3.594 3.613
5 22.111 10.012 6.323 4.608 4.124 4.093
6 22.056 10.458 6.484 5.111 4.652 4.591
7 20.643 10.503 7.088 5.581 5.001 4.769
Table 4.4: The advantage value of the pro-
posed strategy over the myopic strategy based
on my codes, where N = 14, σ = 0.5, λ = 100
and b∗ = 0.97.
τ
c 2 3 4 5 6 7
0 70.258 54.396 49.195 41.069 35.922 31.031
1 55.868 39.371 31.021 27.495 23.577 22.480
2 33.080 34.793 24.643 23.903 17.846 16.078
3 31.833 22.193 22.348 20.457 17.431 14.076
4 29.476 18.869 22.596 17.617 17.274 13.326
5 23.540 22.254 20.601 15.032 12.304 14.494
6 19.456 17.136 16.853 14.812 13.117 8.674
7 15.153 19.731 19.179 12.859 8.327 5.980
From Table 4.3 and Table 4.4, we can intuitively find that the advantage values are decreasing as τ
is increasing for the same number of c. By observing Table 4.3, the advantage value is decreasing as c is
increasing only when τ <4, and the advantage value is increasing as c is increasing when τ >4. However,
there is a big difference in Table 4.4 : the advantage values are decreasing as c is increasing for all τ . In other
words, Table 4.3 strongly verifies the conclusion we got from Chapter 3. In addition, we find that the last
value of the first row in Table 4.3 is an approximate threshold of myopic strategy over proposed strategy,
i.e., there must exist a break-even value in the process when c = 0 and τ increase from 7 to 8. However, this
case does not happen in Table 4.4. We can find that the minimum number 5.98 appeared when c = 7 and
τ = 7, but it still does not meet the approximate threshold of the break-even value. There are many reasons
that can cause this case to happen, but the main reason is that the b∗ = 0.97 is not suitable for our codes.
Hence, we should find an exact b∗ before testing other parameters.
We tried many kinds of situations, however there is no b∗ that can meet a good lower bound for searching
optimal strategies based on N = 14, σ = 0.5, and λ = 100. Hence, we had to change some values of the
parameters to find an exact b∗. Finally, we found b∗ = 0.93 is a good lower bound for searching optimal
strategies based on N = 28, σ = 0.5, λ = 100. Hence, the total number of patients N = 14 is a good
condition for Wang’s simulation, but it is not good enough for our simulation. So in the following, we will
use b∗ = 0.93 for our simulations and increase the total number of patients N from 14 to 28. Since we focus
on the interaction between proposed strategy and myopic strategy, in the following tables we just list the
advantage values of the proposed strategy over the myopic strategy.
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Table 4.5: The advantage values of the proposed strategy over the myopic strategy based on my
codes, where N = 28, σ = 0.5, λ = 100 and b∗ = 0.93.
τ
c 2 3 4 5 6 7 8 9 10 11 12 13 14
0 95.109 92.588 87.348 73.969 66.240 61.842 57.814 53.570 49.469 33.479 22.954 12.609 7.751
1 85.891 66.234 61.350 54.120 48.074 42.391 38.341 38.689 33.123 21.810 18.428 10.068 6.141
2 62.073 57.062 45.747 44.715 37.918 36.898 32.005 31.346 27.227 18.805 15.927 13.869 5.754
3 53.231 42.223 40.695 41.994 32.009 32.888 31.973 28.061 25.454 15.839 16.639 12.942 4.922
4 49.634 37.839 36.414 30.396 32.222 30.922 25.141 23.024 24.220 14.098 11.078 9.117 4.798
5 46.237 42.325 33.198 26.533 30.567 24.888 22.557 22.120 22.491 16.542 10.403 8.559 4.492
6 38.237 34.704 30.113 30.371 28.024 25.535 20.499 18.501 17.881 12.304 13.096 11.772 3.935
7 42.844 35.985 27.403 25.031 16.889 25.206 22.573 18.202 17.441 16.252 11.168 10.919 3.579
8 31.050 27.451 26.681 23.435 21.857 22.225 21.978 20.237 16.659 14.165 12.583 10.876 3.237
9 29.671 23.425 22.424 22.684 19.537 20.295 18.555 17.261 16.230 15.189 11.228 8.168 2.633
10 24.020 22.964 21.203 20.973 21.618 18.422 16.724 17.684 10.011 9.739 8.864 9.864 3.033
11 22.945 18.259 15.491 17.688 16.924 15.891 14.249 10.831 13.388 10.199 9.188 7.336 2.460
12 18.608 14.692 14.456 13.980 15.102 11.524 12.693 10.370 13.658 12.230 8.633 5.491 1.945
13 16.022 13.323 13.416 12.625 10.306 10.930 9.850 9.630 10.277 10.925 7.397 4.559 1.485
14 14.229 12.846 12.557 10.796 9.392 9.081 7.642 5.354 4.547 4.696 2.256 2.818 0.487
By observing Table 4.5, we see that the values are decreasing as τ increases, and the proposed strategy
decreased faster than the myopic strategy. This indicates that if we have the same censored patients, more
patients died cause fewer information collected and lowering the effect of treatment. On the other hand, the
values increased as c increased in both tables, and the proposed strategy increased slower than the myopic
strategy. This indicates that if we have the same number of death patients, then the effect of treatment
depends on the size of the censored patients. As more information is collected, the myopic strategy becomes
optimal if the information is useful. However, the limitations of collected information, along with the pa-
tients be treated the effective information collection rate will gradually decrease then the efficiency of two
strategies will both increase but the rate gradually decreases. Since the myopic strategy always picks up the
better treatment, its advantage should increase faster than the proposed strategy after collecting of sufficient
information. For more details, we draw graphs that offer an intuitive observation.
There are two graphs in Figure 4.1, both of which are two-dimensional. The first graph represents the ad-
vantage values of the proposed strategy over the myopic strategy with different number of dead patients, and
the second graph represents the advantage values with different number of censored patients. By observing
the first graph, we find that the advantage values are decreasing as τ increases, the range of advantage value
decreased from over 85 to slightly larger than 0. The mean of the advantage values decreasing marginally,
and it decreased from over 50 to slightly larger than 5. On the other hand, we can find the advantage values
are decreasing as c increases in the second graph. The range of advantage values decreased from over 95 to
slightly larger than 0, and the mean of advantage values have a larger range of diminishing, as it decreased
from over 55 to slightly less than 10. In addition, we also draw some three-dimensional graphs to show the
overall trends and the relationship between τ and c.
35
Figure 4.1: Boxplot for the advantage of the proposed strategy over the myopic strategy, where
N = 28, σ = 0.5, λ = 100 and b∗ = 0.93.
l
l
l
l
l
l
l
l
l
l
l
tau2 tau4 tau6 tau8 tau10 tau12 tau14
0
20
40
60
80
N=28, Sigma=0.5, Lambda=100, bstar=0.93
The number of died patients
Th
e 
ad
va
n
ta
ge
 va
lu
es
 o
f p
ro
po
se
d 
st
ra
te
gy
 o
ve
r 
m
yo
pi
c 
st
ra
te
gy
l
l l
l
l
c=0 c=2 c=4 c=6 c=8 c=10 c=12 c=14
0
20
40
60
80
N=28, Sigma=0.5, Lambda=100, bstar=0.93
The number of censored patients
Th
e 
ad
va
n
ta
ge
 va
lu
es
 o
f p
ro
po
se
d 
st
ra
te
gy
 o
ve
r 
m
yo
pi
c 
st
ra
te
gy
Figure 4.2: Three-dimensional graphs for the advantage of the proposed strategy over the myopic
strategy, where N = 28, σ = 0.5, λ = 100 and b∗ = 0.93
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There are also two three-dimensional graphs in Figure 4.2. In order to more clearly observe, the second
graph is the first graph after rotating 180 degrees. By observing Figure 4.2, we find the advantage values
formed an inclined surface. This indicates that as c and τ moved towards 14, the advantage of the proposed
strategy over the myopic strategy decreased in general.
We are also interested in testing the changes if we increase the total number of patients. In the follow up
simulation, all the initial parameters are unchanged but N is increased to 36. By observing the left graph
of Figure 4.3, we intuitively find that the mean of advantage values decreased very sharply. The range of
advantage values reduced from slightly less than 150 to over −20. And all advantage values are negative when
τ > 16, which means the myopic strategy completely dominates the proposed strategy if τ > 16. On the other
hand, by observing the right graph of Figure 4.3. We find the mean advantage values decreases very slowly,
and the break-even values appeared at each number c. Comparing with Figure 4.2, we can say that after
N increased, the range of advantage values became wider and the myopic strategy completely dominated
the proposed strategy before half the number of total patients. Hence, if the number N is increased, more
information is collected and it is more suitable for the myopic strategy.
Figure 4.3: Boxplot for the advantage of the proposed strategy over the myopic strategy, where
N = 36, σ = 0.5, λ = 100 and b∗ = 0.93.
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Through the analysis of selected patients N , we can say the myopic strategy is asymptotically optimal
for a large number of total patients. In addition, we also verified the changing trends in the function 4 and
verified a good lower bound b∗ = 0.93 for searching for the optimal strategy. In the next subsection, we will
see that detect the change of our simulations depends on different censoring times.
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4.3.2 Different censoring time
In our model, there is an exponential inter-selection time which cumulative distribution function H(t) =
1 − e−tσ, where t ≥ 0. The expected value of inter-selection time indicates the average censoring time of
the clinical trials, and the rate parameter σ plays a key role in arrival lifetime distribution. Hence, we can
use the different σ to achieve the changes in simulation which depends on different censoring times. In this
section, we will gradually reduce the value of σ from 0.5 to 0.1 which means the censoring time increases
from 2 days to 10 days. Since the case of σ = 0.5 has been listed in Table 4.5, we just list the values for
σ = 0.2 and σ = 0.1 in this section. In order to test the effect of different σ, some of the initial parameters
for simulations have been specified. These include:
• the total number of selected patients N = 28;
• the constant expected survival time λ = 100 on known treatment;
• a good lower bound b∗ = 0.93 for searching optimal strategies.
Table 4.6: The advantage values of the proposed strategy over the myopic strategy based on my
codes, where N = 28, σ = 0.2, λ = 100 and b∗ = 0.93.
τ
c 2 3 4 5 6 7 8 9 10 11 12 13 14
0 91.068 88.965 82.912 79.784 78.102 68.021 61.187 52.059 43.085 33.853 21.316 11.920 9.569
1 89.317 77.481 75.966 72.162 70.348 63.011 50.152 47.619 35.882 29.711 18.858 10.677 6.062
2 80.587 67.224 64.919 68.482 62.842 60.723 53.993 45.265 32.234 25.473 11.498 4.072 1.056
3 70.091 63.266 59.991 59.613 57.719 53.271 46.080 38.787 30.120 18.722 10.961 2.116 0.983
4 64.961 56.562 48.021 49.147 48.675 45.320 38.877 31.172 28.803 21.871 7.377 1.198 -0.361
5 50.997 52.663 44.258 43.107 42.523 41.473 31.360 28.355 25.564 23.508 6.962 0.233 -1.564
6 49.095 45.904 39.330 38.299 35.038 36.230 30.691 23.100 22.268 20.186 4.210 -1.761 -3.428
7 39.651 38.953 32.929 29.357 22.448 21.737 27.801 19.428 19.166 16.964 3.423 -3.249 -5.347
8 47.408 33.748 28.884 23.759 18.097 22.912 23.716 12.397 17.379 10.123 2.351 -3.843 -8.203
9 38.088 29.312 22.882 18.880 15.175 14.629 12.428 8.090 5.978 4.480 2.109 -5.408 -10.993
10 29.973 28.858 18.557 13.474 11.645 10.316 9.318 6.702 3.772 2.709 0.359 -6.560 -13.045
11 24.403 21.941 14.223 10.879 9.455 7.194 6.410 5.971 1.570 0.170 -4.952 -8.145 -15.435
12 18.274 13.078 11.296 9.541 6.934 4.943 3.862 1.269 0.973 -5.784 -9.875 -11.804 -19.224
13 10.301 9.519 7.780 4.933 2.707 2.145 1.245 0.793 -1.997 -7.842 -10.878 -13.079 -22.865
14 6.816 5.056 3.714 0.761 1.936 1.024 0.768 -2.171 -5.984 -9.036 -12.828 -16.830 -27.341
By observing Table 4.6, we find that the overall trends are the same as in Table 4.5. That is, the advan-
tage values are decreasing as τ and c increase. We also find that the range of advantage values is increasing
and lots of negative numbers appear. These illustrate that decreasing the number of σ can make the myopic
strategy dominate the proposed strategy faster. The reason is that when σ decreased from 0.5 to 0.2, the
censoring time increased from 2 days to 5 days. The increased censoring time must cause more information
to be collected. This information is embodied in the number of patient deaths. For example, if a patient
lived for 3 days after treatment, then they should be considered as dead if the censoring time is 5 days. On
the other hand, they may be considered as alive if the censoring time is 2 days. In another words, σ just
determines the time of gathering information in proposed strategies especially if the inverting for very little
information at initial phase.
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Table 4.7: The advantage values of the proposed strategy over the myopic strategy based on my
codes, where N = 28, σ = 0.1, λ = 100 and b∗ = 0.93.
τ
c 2 3 4 5 6 7 8 9 10 11 12 13 14
0 78.838 69.077 61.969 49.924 31.980 22.380 13.558 2.256 -16.187 -14.609 -27.239 -46.512 -57.345
1 69.491 33.446 20.310 23.541 16.422 7.266 -0.794 -16.091 -22.658 -31.837 -49.621 -50.942 -58.892
2 44.433 23.432 14.559 6.033 1.763 -6.636 -17.682 -30.617 -34.232 -44.463 -50.392 -58.138 -62.348
3 28.059 6.381 -2.407 -0.685 -10.975 -16.966 -28.277 -39.490 -48.174 -53.101 -57.429 -60.479 -62.293
4 18.051 5.331 -6.438 -15.077 -29.299 -25.773 -37.527 -41.846 -50.714 -59.887 -63.529 -59.498 -65.234
5 2.634 -12.143 -17.569 -21.884 -23.757 -37.798 -40.089 -41.289 -52.532 -57.783 -64.697 -63.940 -62.324
6 -18.491 -9.333 -11.118 -26.666 -28.411 -38.930 -39.264 -44.917 -49.862 -60.375 -56.717 -61.958 -63.519
7 -10.394 -14.753 -14.714 -18.189 -41.904 -34.588 -42.771 -49.188 -57.704 -66.984 -61.025 -63.665 -64.253
8 -14.493 -9.401 -13.185 -19.099 -25.656 -40.365 -45.464 -47.084 -51.062 -54.166 -63.455 -60.173 -66.274
9 -20.252 -8.743 -19.919 -22.983 -34.474 -40.127 -38.669 -50.222 -52.782 -60.618 -57.564 -63.428 -61.921
10 -17.495 -24.951 -8.188 -21.857 -23.026 -29.448 -39.227 -50.278 -47.758 -51.074 -55.868 -58.074 -53.298
11 -24.897 -13.228 -12.309 -24.676 -28.071 -26.845 -39.460 -46.679 -47.734 -46.676 -54.415 -57.645 -62.231
12 -25.719 -1.398 -10.972 -35.755 -27.668 -30.655 -36.089 -33.325 -39.515 -44.282 -44.393 -50.544 -53.283
13 -29.558 -20.048 -27.538 -34.159 -23.633 -26.420 -35.912 -38.819 -38.594 -40.606 -37.666 -41.450 -59.773
14 -21.799 -2.069 -17.105 -23.860 -23.216 -24.825 -27.234 -35.110 -29.207 -30.337 -33.563 -36.125 -43.205
In order to more clearly verify the characteristic of σ, we further decrease its value to 0.1. Although we
just take it from 0.2 down to 0.1, the censoring time has increased by 5 days. By observing Table 4.7, we find
more negative numbers which indicate the advantage of proposed strategies disappears faster than before.
Also different from the past, the advantage values sharply decline when c is smaller than 5 and τ is larger than
7. Relative to Table 4.6, the difference between the two strategies is almost the same at the initial phase, but
a large gap appears at the finial phase. As c increased, the advantage values also sharply decline after a short
stabilization. Compared with Table 4.4, the σ decreased from 0.5 to 0.1 caused the censoring time to increase
from 2 days to 10 days. This is a big variable change in clinical trials, since there are more days of censoring,
and more patients are considered dead. It is clear that 8 days delay causes a big difference. There is an
overall reduction of advantage values in Table 4.7. This means that σ = 0.1 not only reduced the gap of the
two strategies at the initial phase but also reduced the time of the myopic strategy over the proposed strategy.
Figure 4.4 shows the changes when σ decreases from 0.5 to 0.1. By observing the advantage values as
they change with c (upper row of Figure 4.4 ), we find that the mean advantage values change from sharp to
flat. When σ = 0.5 all advantage values are positive and their mean converge to 20, so the proposed strategy
is completely in a dominant position. When σ = 0.2 most of the advantage values are positive but a few of
them are negative, which indicates the myopic strategy is gradually better than the proposed strategy. When
σ = 0.1, we find that most of the advantage values are negative and their mean converge to -20, so the myopic
strategy is in a dominant position. On the other hand, by observing the advantage values change with τ
(lower row of Figure 4.4 ), we find that the mean of advantage values are always declining. In particular, all
of the mean of advantage values are negative when σ = 0.1.
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Figure 4.4: Boxplot for the advantage value of the proposed strategy over the myopic strategy with
different number of σ
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Through the above analysis, we found the role of σ in our simulations. With the reduction of the variable
σ, the censoring time gradually increased. Longer censoring time should cause the number of dead patients
increase. Hence, we think a smaller σ means more information was collected in the unknown treatment. The
valid information more saturated cause the efficiency of proposed strategies to decrease faster, but the myopic
strategy always keeps the most efficient solution. Hence, the advantage value of the proposed strategy over
the myopic strategy should decrease faster. In the next subsection, we will detect the last key variable λ
which is the expected maximum lifetime in the known treatment.
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4.3.3 Different known expect lifetime
In our prototypical example, λ represents the expectation of survival time for the known treatment. By
analyzing the advantage values of the proposed strategy over the myopic strategy based on different choices
of λ, we can detect its role in our model and the influence on both strategies.
In this subsection, we applied three different choices of λ to our simulation. Since the case of λ = 100 has
been listed in Table 4.5, we just list the tables for λ = 90 and λ = 80 here. In order to test the effect on the
different choices of λ, some of the initial parameters for the simulation have been specified. These include:
• the total number of selected patients N = 28;
• the rate parameter of arrival time distribution σ = 0.5;
• a good lower bound b∗ = 0.93 for searching optimal strategies.
Table 4.8: The advantage values of the proposed strategy over the myopic strategy based on my
codes, where N = 28, σ = 0.5, λ = 90 and b∗ = 0.93.
τ
c 2 3 4 5 6 7 8 9 10 11 12 13 14
0 62.822 52.067 46.638 37.497 32.582 28.993 20.955 13.182 8.382 4.992 2.526 -3.317 -4.059
1 45.111 36.755 30.769 24.327 20.918 18.148 12.327 8.830 3.747 1.755 -1.379 -2.427 -2.254
2 32.371 29.767 22.065 20.559 16.849 16.281 10.262 7.918 4.127 -0.263 -1.046 -1.427 -0.970
3 30.889 22.124 20.224 19.027 15.623 14.192 11.154 5.594 1.756 -1.351 -1.237 -2.008 -3.466
4 33.319 24.323 17.534 14.337 10.802 13.973 9.860 5.508 2.239 -3.220 -4.248 -4.318 -5.687
5 14.386 20.468 13.775 15.579 11.822 8.375 4.713 2.069 0.339 -2.856 -5.199 -4.971 -7.449
6 18.812 18.462 14.334 9.928 8.432 5.801 4.266 1.852 -2.924 -4.819 -5.274 -5.552 -8.800
7 15.885 15.988 10.786 10.687 10.106 8.413 6.870 1.773 -3.498 -5.331 -5.679 -8.592 -8.307
8 16.875 7.407 10.395 11.176 10.523 9.607 6.311 -2.750 -4.491 -6.313 -5.166 -7.137 -10.666
9 13.711 13.928 8.733 7.242 3.460 1.490 -3.547 -4.730 -6.860 -4.849 -9.722 -11.623 -12.023
10 13.690 9.762 11.018 7.952 7.914 5.181 4.945 0.305 -3.604 -3.777 -5.428 -9.177 -11.931
11 11.609 6.953 4.915 6.340 7.461 4.412 2.821 -4.213 -7.224 -4.455 -8.474 -11.146 -13.367
12 14.943 7.132 7.623 4.660 2.660 0.541 -2.256 -4.234 -9.934 -7.965 -10.702 -13.822 -11.179
13 10.496 8.304 5.165 1.523 -2.511 -3.521 -4.976 -7.830 -5.999 -9.626 -13.996 -10.737 -12.072
14 8.324 4.031 0.479 -1.892 -4.324 -8.838 -6.425 -11.333 -8.421 -10.923 -15.855 -14.311 -16.645
By observing Table 4.8, we find that a slight reduction of advantage values appears at the initial phase,
which means a reduced λ causes the gap between the two strategies to decrease at the initial phase. The
reason is that a smaller λ should lead more strategies to choose the unknown treatment at the initial phase.
Hence, the gap must be decreased by more patients that received the same treatment. In addition, the
advantage values are decreasing very slowly as τ and c increase, which means the proposed strategy and
myopic strategy both have a steady upward trend but the myopic strategy is faster than the proposed strat-
egy. Compared with Table 4.5, we find that the range of advantage values increased and more values are
becoming negative. Hence, if we reduce the number λ, it causes the myopic strategy to completely dominate
the proposed strategy earlier. In order to clearly verify the characteristic of λ, we further decrease its value
to 80.
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Table 4.9: The advantage values of the proposed strategy over the myopic strategy based on my
codes, where N = 28, σ = 0.5, λ = 80 and b∗ = 0.93.
τ
c 2 3 4 5 6 7 8 9 10 11 12 13 14
0 44.037 38.726 30.630 24.547 20.157 15.385 10.341 8.588 6.599 4.717 1.767 -2.965 -3.624
1 37.435 28.768 22.534 17.350 11.713 7.711 5.013 3.578 2.550 1.501 -2.150 -1.750 -2.802
2 29.912 23.274 21.647 18.366 11.715 8.486 6.765 4.780 3.812 -0.685 -1.124 -1.828 -1.291
3 22.605 19.149 15.432 11.238 8.877 7.469 5.337 2.421 0.231 -2.398 -1.747 -3.282 -4.036
4 18.227 15.460 12.348 9.869 11.853 9.364 7.981 3.556 -1.649 -3.657 -3.793 -5.921 -6.040
5 15.786 14.185 11.152 10.155 8.709 6.661 3.452 0.554 -2.883 -5.475 -6.372 -6.234 -5.729
6 11.211 9.082 7.365 4.439 3.091 1.028 0.975 -3.466 -6.030 -4.692 -5.196 -7.787 -8.005
7 8.289 4.123 6.504 3.827 -0.121 -2.625 -5.998 -4.222 -6.329 -7.067 -6.845 -8.459 -11.662
8 5.214 2.377 0.010 -2.071 -3.946 -8.394 -7.164 -10.582 -12.952 -14.837 -13.675 -13.018 -14.186
9 4.806 1.828 -4.951 -6.264 -5.732 -6.733 -9.477 -11.737 -13.792 -14.276 -16.431 -15.908 -17.067
10 2.893 -3.121 -5.838 -11.974 -7.487 -10.157 -13.707 -15.473 -16.593 -17.306 -19.635 -23.810 -23.198
11 1.840 -6.740 -7.882 -5.404 -8.307 -10.777 -14.097 -16.910 -14.841 -18.857 -16.346 -20.517 -23.0431
12 -2.168 -4.704 -6.452 -8.556 -13.874 -14.491 -16.969 -18.021 -20.566 -22.588 -24.938 -24.224 -27.965
13 -3.545 -5.576 -8.721 -11.666 -15.319 -17.532 -20.748 -22.547 -26.912 -28.601 -32.557 -35.819 -35.586
14 -7.332 -10.417 -14.090 -12.245 -16.224 -20.294 -19.201 -21.256 -24.332 -26.987 -29.684 -32.634 -36.957
By observing Table 4.9, we find that the advantage values are greatly reduced at the initial phase, and
the lower bound range becomes more negative. The overall trend of advantage values decreased very slowly
as τ and c increased. Compared with Table 4.8, we find that more advantage values become negative, and
do so sooner. This indicates that the myopic strategy dominates the proposed strategy earlier. In order to
provide a visual observation, we graph the advantage values for different choices of λ.
Figure 4.5 shows the changes when λ gradually decreases from 100 to 90, then to 80. By observing the
advantage values as they change with c (upper row of Figure 4.5 ), we find that the upper bound range of
advantage values gradually decreased and the lower bound range gradually increased. When λ decreased
from 100 to 90 the mean of the advantage values changed from sharp to flat and converged to 10. Most of the
advantage values are positive, with only a few negative numbers appearing when c < 3. When we decreased
λ from 90 to 80, the mean of the advantage values changed back from flat to sharp and converged to -20. It is
obvious that the proposed strategy is completely dominant since most of the advantage values are negative.
On the other hand, by observing the advantage values as they change with τ (lower row of Figure 4.4 ), we
find that the mean of the advantage values are always declining and converge to 5 when λ changes from 100
to 90. When we decreased λ from 90 to 80, most of the mean of advantage values are negative and converge
to -5. Hence, we can say a smaller λ causes more advantage values to be reduced at the initial phase, and
the overall trend is that the graphs always decreases at a constant rate as τ and c increase.
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Figure 4.5: Boxplot for the advantage value of the proposed strategy over the myopic strategy with
different number of λ
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4.4 Summary
Motivated by clinical trial problems, this dissertation studies sequential selection with censored lifetime.
The objective is to maximize some combination of total expected rewards from all selections. Following the
Bayesian approach and employing the technique of dynamic programming, these sequential selection pro-
cesses are formulated as general controlled stochastic processes. Some of the results for sequential selection
with immediate responses are generalized to the sequential selection with censored lifetime, and most of these
generalization are elucidated by working out details for the clinical trial problem. Optimality equations have
also been derived, and we focus on solving a particular simple example. There are two treatments, and the
patients’ lifetime after the treatments are assumed to be exponentially distributed. One of the treatments
has a known expected lifetime λ. The other has an unknown expected lifetime θ−1, where θ has a Gamma
(η, τ) prior distribution. The random times between any two continuous treatments of the patients follow
the exponential distribution with known mean σ−1. We then look for the optimal strategies and detailed
solutions. These are described by the function 4, which is the advantage of the unknown treatment over
the known treatment. We show how this function determines the optimal strategies by specifying some
break-even values of the parameters. The monotonicity property of the optimal strategies is discovered, and
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the solutions for the case of two allocations of treatments is worked out and discussed in detail. Finally
we corrected some errors in Wang’s[40] simulations and use R to rewrite the code for the simulations. We
compare our results with Wang’s, and verify that in the general case the myopic strategy is not optimal at
the initial phase but gradually dominates the proposed strategy. We also verified the changing trends in
the function 4 and found a good lower bound b∗ = 0.93 for searching the optimal strategy. We observe
the changes that occur after altering our parameters. In particular, when we increase the total number of
patients we find that the myopic strategy completely dominates the proposed strategy, and does so earlier.
A larger number N can provide more initial history information for the unknown treatment. The increase in
the range of advantage values at the initial phase indicates that the proposed strategy has a huge advantage.
However, more adequate information has also led the myopic strategy to quickly improve its accuracy. In
addition, with more selected patients there is a higher risk. If the unknown treatment is no better than the
known treatment in terms of immediate payoff and the difference is bounded by a calculated risk, then it is
still optimal to select the unknown treatment in order to benefit from information gathering. How to control
this calculated risk is an avenue of further research. By observing the result of reducing the value of σ, we
find that longer censoring times lead to more information being collected in the unknown treatment. More
valid information improves the efficiency of both strategies, but the myopic strategy always improves at a
faster rate and keeps the most efficient solution. Hence, there is no major difference at the initial phase if
we use a smaller number of σ, but it should cause the velocity of the advantage values to decrease faster.
On the other hand, the velocity of the advantage values decrease almost at a constant rate when we reduce
λ. Although the myopic strategy dominates the proposed strategy earlier when either σ or λ is reduced, the
biggest difference is that reducing λ causes the advantage values to decrease at the initial phase. A smaller λ
should lead more strategies to choose the unknown treatment at the initial phase, and the gap must decrease
when more patients receive the same treatment.
In our simulation, we used a uniform sequence for discount factors to make the calculation quick and easy.
In practice, the uniform sequence is just a special case of geometric sequence. Since the geometric sequence
more universal in real life, so a general geometric sequence will apply to our simulation in the future research.
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Appendix A
Appendix
## Nsimulat ion i s a program des igned by R. The o b j e c t i v e i s to see the d i f f e r e n c e o f the t o t a l
## expec ted l i f e t i m e s between proposed s t r a t e g y and myopic s t r a t e g y . This program cons ide r s the
## motivated example wi th any number o f s e l e c t e d pa t i en t s , any number o f sigma , any number o f
## known expec t l i f e t i m e and any number o f i n i t i a l lower bound to make the proposed s t r a t e g y
## con s i s t e n t l y b e t t e r than the myopic s t r a t e g y .
Nsimulat ion<−function ( npat ient , sigma , lambda , c s t a r ){
#i n i t i a l s imu la t i on r e p l i c a t i o n 10000 t imes
n t r i a l<− 10000
#i n i t i a l t o t a l number o f censored p a t i e n t s
Nbank<−npat i ent
#i n i t i a l t o t a l number o f dea ths
Ntau<−npat ient−1
#i n i t i a l e xpec t va lue o f known treatment lambda
Lambda<−rep ( n t r i a l , ( 1/lambda ) )
#i n i t i a l proposed matrix s i z e
proposed<−matrix ( 0 . 0 , Nbank , Ntau )
#i n i t i a l myopic matrix s i z e
myopic<−matrix ( 0 . 0 , Nbank , Ntau )
#i n i t i a l d e l t a matrix s i z e
de l t a<−matrix ( 0 . 0 , Nbank , Ntau )
#i n i t i a l e xpec t matrix s i z e
expect<−matrix ( 0 . 0 , Nbank , Ntau )
for (m in 1 :Nbank){
for (n in 1 : Ntau ){
#i n i t i a l dea ths va lue f o r proposed s t r a t e g y
tau<−rep (n+1, n t r i a l )
#i n i t i a l dea ths va lue f o r myopic s t r a t e g y
t au s ta r<−tau
#i n i t i a l censored p a t i e n t s va lue f o r proposed s t r a t e g y
nbank<−rep (m, n t r i a l )
#i n i t i a l censored p a t i e n t s va lue f o r myopic s t r a t e g y
nbankstar<−nbank
#i n i t i a l h i s t o r y
h i s<−( ( nbank+tau)>npat i ent )+(1−((nbank+tau)>npat i ent ) )∗ ( ( l==npat i ent )
+(1−( l==npat i ent ) )∗ ( c s t a r +(1.0− c s t a r )∗ ( nbank+tau )/npat i ent ) )
#i n i t i a l e ta f o r proposed s t r a t e g y
eta<−h i s∗lambda∗ ( tau−1)
#i n i t i a l e ta f o r myopic s t r a t e g y
e t a s t a r<−eta
#cumulate t o t a l time o f two s t r a t e g i e s from the f i r s t s e l e c t e d pa t i e n t
for ( l in 1 : npat i ent ){
#use rgamma to genera te t h e t a which i s unknown hazard ra t e
theta<−rgamma( n t r i a l , tau , eta )
#genera te parameter o f l i f e t i m e d i s t r i b u t i o n f o r unknown treatment
param<−lapply (as . l i s t ( 1 : n t r i a l ) , function ( a ){c ( theta [ a ] , ( nbank+1)[ a ] ) } )
#genera te l i f e t i m e s f o r ( nbank+1) censored p a t i e n t s
l i f e<−lapply (param , function ( a ){rexp ( a [ 2 ] , a [ 1 ] ) } )
#genera te parameter o f l i f e t i m e d i s t r i b u t i o n f o r known treatment
paramstar<−lapply (as . l i s t ( 1 : n t r i a l ) , function ( a ){c (Lambda [ a ] , ( nbankstar +1)[ a ] ) } )
#genera te l i f e t i m e s f o r ( nbanks tar+1) censored p a t i e n t s
l i f e s t a r<−lapply ( paramstar , function ( a ){rexp ( a [ 2 ] , a [ 1 ] ) } )
#genera te the censor ing time
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censor<−rexp ( n t r i a l , sigma )
#genera te s u r v i v a l l i f e t i m e o f proposed treatment
s u r v i v a l<−mapply ( function ( a , b){ sapply ( a , function (c ){min(c , b )} )} , l i f e , c ensor )
#update e ta f o r proposed treatment
eta<−eta+colSums ( s u r v i v a l )
#genera te s u r v i v a l l i f e t i m e o f myopic treatment
s u r v i v a l s t a r<−mapply ( function ( a , b){ sapply ( a , function (c ){min(c , b )} )} , l i f e s t a r , censor )
#update ea t f o r myopic s t r a t e g y
e t a s t a r<−e t a s t a r+colSums ( s u r v i v a l s t a r )
#genera te dea ths number o f proposed s t r a t e g y
death<−mapply ( function ( a , b){a<=b} , l i f e , censor )
#update dea ths number and censored p a t i e n t s number f o r proposed s t r a t e g y
tau<−tau+colSums ( death )
nbank<−nbank+1−colSums ( death )
#genera te dea ths number o f myopic s t r a t e g y
deaths ta r<−mapply ( function ( a , b){a<=b} , l i f e s t a r , censor )
#update dea ths number and censored p a t i e n t s number f o r myopic s t r a t e g y
t au s ta r<−t au s ta r+colSums ( deaths ta r )
nbankstar<−nbankstar−colSums ( deaths ta r )
#update in format ion o f h i s t o r y f o r next s t a g e
h i s<−( ( nbank+tau)>npat i ent )+(1−((nbank+tau)>npat i ent ) )∗ ( ( l==npat i ent )
+(1−( l==npat i ent ) )∗ ( c s t a r +(1.0− c s t a r )∗ ( nbank+tau )/npat i ent ) )
#update c r i t e r i o n o f ea t f o r proposed s t r a t e g y
c r i e t a<−h i s∗lambda∗ ( tau −1.0)
#update c r i t e r i o n o f ea t f o r myopic s t r a t e g y
c r i e t a s t a r<−1∗lambda∗ ( taustar −1.0)
#update t o t a l s u r v i v a l l i f e t i m e o f proposed s t r a t e g y
unknown<−unknown+lambda∗ ( eta<c r i e t a )+( eta/ ( tau −1.0))∗ ( eta>=c r i e t a )
#update t o t a l s u r v i v a l l i f e t i m e o f myopic s t r a t e g y
known<−known+lambda∗ ( e ta s ta r<c r i e t a s t a r )+( e t a s t a r/ ( taustar −1.0))∗ ( e ta s ta r>=c r i e t a s t a r )
}
proposed [m, n ]<−mean(unknown)
myopic [m, n ]<−mean(known)
de l t a [m, n ]<−proposed [m, n]−myopic [m, n ]
expect [m, n ]<−max( proposed [m, n ] , myopic [m, n ] )
}
}
}
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